Research Protocol
ATTACG: Anakinra versus Treatment as
usual in the Treatment of ACute Gout
Version 5: 9 February 2016
Research Protocol NL52526.044.15 / ATTACG
Project Information
Study title:
Anakinra versus treatment as usual in the treatment of acute
gout
Short title:
ATTACG
Dutch title:
Anakinra versus standaardbehandeling bij acute jicht
Protocol ID:
NL52526.044.15
EudraCT number:
2015-000696-27
Version:
5
Date:
9 February 2016
Coordinating investigator:
C.A. (Carly) Janssen MSc
Principal investigator:
Prof. dr. M.A.F.J. (Mart) van de Laar
Multicenter research (investigator
per site):
1. Medisch Spectrum Twente, Enschede ( Principal
site): M.A.F.J. van de Laar & H.E. Vonkeman
2. Rijnstate, Velp: M. Janssen
3. VieCuri Medical Centre, Venlo: T. Jansen
4. Medisch Center Leeuwarden, Leeuwarden: R. Bos
5. Ziekenhuisgroep Twente, Almelo/Hengelo: H. Baan
6. Röpcke-Zweers Ziekenhuis, Hardenberg: C. Lebrun
Sponsor (in Dutch
verrichter/opdrachtgever):
Prof. dr. M.A.F.J (Mart) van de Laar (University of Twente,
UT)
Subsidizing parties:
ZonMw, Sobi
Independent physician:
Dr. W.M. Smit (Department of Internal Medicine, Medisch
Spectrum Twente, Enschede)
Pharmacy:
Slotervaart Hospital
Department of Pharmacy & Pharmacology
Louwesweg 6
1066 EC Amsterdam, the Netherlands
2
Research Protocol NL52526.044.15 / ATTACG
Table of Contents
1.
INTRODUCTION AND RATIONALE............................................................................................................. 9
2.
STUDY AIMS ........................................................................................................................................... 10
PRIMARY OBJECTIVE ............................................................................................................................................... 10
SECONDARY OBJECTIVES .......................................................................................................................................... 10
3.
STUDY DESIGN ....................................................................................................................................... 11
DURATION AND DESIGN .......................................................................................................................................... 11
MULTI-CENTER RESEARCH ....................................................................................................................................... 11
COORDINATING PHARMACY ..................................................................................................................................... 11
4.
STUDY POPULATION .............................................................................................................................. 12
POPULATION......................................................................................................................................................... 12
INCLUSION CRITERIA ............................................................................................................................................... 12
EXCLUSION CRITERIA............................................................................................................................................... 12
5.
TREATMENT OF SUBJECTS ...................................................................................................................... 14
INVESTIGATIONAL TREATMENT.................................................................................................................................. 14
COMPARATOR TREATMENT ...................................................................................................................................... 14
NON-ACTIVE PLACEBOS ........................................................................................................................................... 14
URATE LOWERING THERAPY (ULT) ............................................................................................................................ 14
RESCUE MEDICATION ............................................................................................................................................. 14
REFRACTORY GOUT ATTACK ..................................................................................................................................... 15
6.
INVESTIGATIONAL TREATMENT ............................................................................................................. 16
NAME AND DESCRIPTIVE.......................................................................................................................................... 16
SUMMARY OF FINDINGS FROM PRE-CLINICAL STUDIES ................................................................................................... 16
SUMMARY OF FINDINGS FROM CLINICAL STUDIES.......................................................................................................... 16
SUMMARY OF KNOWN AND POTENTIAL RISKS AND BENEFITS ........................................................................................... 17
DESCRIPTION AND JUSTIFICATION OF ROUTE OF ADMINISTRATION AND DOSAGE ................................................................. 17
PREPARATION AND LABELLING OF INVESTIGATIONAL MEDICINAL PRODUCT......................................................................... 17
DRUG ACCOUNTABILITY........................................................................................................................................... 17
7.
NON-INVESTIGATIONAL TREATMENT .................................................................................................... 19
NAME AND DESCRIPTION OF AVAILABLE SOC TREATMENTS ............................................................................................. 19
Colchicine...................................................................................................................................................... 19
NSAID, naproxen........................................................................................................................................... 19
Systemic corticosteroid, prednisolon ............................................................................................................ 19
URATE LOWERING THERAPY .................................................................................................................................... 19
NON-ACTIVE SOC PLACEBOS .................................................................................................................................... 19
DOSAGE AND METHOD OF ADMINISTRATION ............................................................................................................... 19
PREPARATION AND LABELLING OF NON-INVESTIGATIONAL MEDICINAL PRODUCT ................................................................. 20
DRUG ACCOUNTABILITY........................................................................................................................................... 20
8.
METHODS .............................................................................................................................................. 21
STUDY ENDPOINTS ................................................................................................................................................. 21
Primary endpoint .......................................................................................................................................... 21
Secondary endpoints of 3 month randomized controlled trial ..................................................................... 21
4
Research Protocol NL52526.044.15 / ATTACG
Secondary endpoints of 9 month open label study extension ...................................................................... 21
DATA COLLECTION ................................................................................................................................................. 21
DATA COLLECTION TOOLS ........................................................................................................................................ 23
Patient numbering ........................................................................................................................................ 23
Baseline characteristics ................................................................................................................................ 23
Uric acid and CRP measurement .................................................................................................................. 23
Patient flare diary ......................................................................................................................................... 23
Patient reported outcomes (PROs) ............................................................................................................... 23
Side effects , AE and SAE .............................................................................................................................. 24
Direct and indirect costs ............................................................................................................................... 25
Study drop-out or completion....................................................................................................................... 25
DISTRIBUTION OF MEDICINES TO PARTICIPATING CENTERS .............................................................................................. 25
RANDOMIZATION, BLINDING AND TREATMENT ALLOCATION............................................................................................ 25
WITHDRAWAL OF INDIVIDUAL SUBJECTS FROM THE STUDY ............................................................................................. 26
REPLACEMENT OF INDIVIDUAL SUBJECTS AFTER WITHDRAWAL FROM THE STUDY ................................................................. 26
FOLLOW-UP OF SUBJECTS WITHDRAWN FROM STUDY .................................................................................................... 26
FOLLOW-UP OF SUBJECTS WITHDRAWN FROM TREATMENT ............................................................................................ 26
PREMATURE TERMINATION OF THE STUDY................................................................................................................... 26
9.
SAFETY REPORTING................................................................................................................................ 27
SECTION 10 WMO EVENT ...................................................................................................................................... 27
SAFETY MONITORING.............................................................................................................................................. 27
AE REPORTING ...................................................................................................................................................... 27
SAE REPORTING .................................................................................................................................................... 28
SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTIONS REPORTING ................................................................................. 28
FOLLOW-UP OF AE AND SAE ................................................................................................................................... 29
ANNUAL SAFETY REPORT ......................................................................................................................................... 29
DATA SAFETY MONITORING BOARD .......................................................................................................................... 29
10.
DATA ANALYSES ................................................................................................................................ 30
POPULATIONS ....................................................................................................................................................... 30
PRIMARY EFFICACY ANALYSES ................................................................................................................................... 30
MISSING DATA ...................................................................................................................................................... 31
SECONDARY ANALYSES ............................................................................................................................................ 31
SAFETY ANALYSES .................................................................................................................................................. 31
COST EFFECTIVENESS ANALYSES ................................................................................................................................ 32
SAMPLE SIZE CONSIDERATIONS ................................................................................................................................. 32
11.
ETHICAL CONSIDERATIONS ................................................................................................................ 33
REGULATORY AND ETHICAL COMPLIANCE .................................................................................................................... 33
RECRUITMENT AND INFORMED CONSENT PROCEDURES .................................................................................................. 33
COMPENSATION FOR INJURY .................................................................................................................................... 33
12.
ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION .......................................................... 34
HANDLING DATA AND DOCUMENTS ........................................................................................................................... 34
MONITORING AND QUALITY ASSURANCE..................................................................................................................... 34
PROTOCOL ADHERENCE AND AMENDMENTS ................................................................................................................ 34
ANNUAL PROGRESS REPORT ..................................................................................................................................... 35
END OF STUDY REPORT............................................................................................................................................ 35
5
Research Protocol NL52526.044.15 / ATTACG
PUBLIC DISCLOSURE AND PUBLICATION POLICY ............................................................................................................. 35
13.
STRUCTURED RISK ANALYSIS ............................................................................................................. 36
POTENTIAL RISKS AND CONCERNS RELATED TO THIS STUDY.............................................................................................. 36
Summary anakinra and gout studies ............................................................................................................ 36
Risks and concerns related to anakinra ........................................................................................................ 36
Other risks and concerns .............................................................................................................................. 37
REDUCING AND MANAGING THE POTENTIAL RISKS AND CONCERNS ................................................................................... 37
14.
REFERENCE LIST ................................................................................................................................. 39
15.
APPENDICES ...................................................................................................................................... 43
I.
II.
III.
IV.
CRF INFORMATION ....................................................................................................................................... 43
PATIENT FLARE DIARY ..................................................................................................................................... 43
PROS QUESTIONNAIRES ................................................................................................................................. 43
DSMB CHARTER .......................................................................................................................................... 43
6
Research Protocol NL52526.044.15 / ATTACG
List of abbreviations
MSU
Monosodium urate
NSAIDs
Non-steroidal anti-inflammatory drugs
SoC
Standard of Care
ULT
Urate lowering therapy
IL
Interleukin
TNF
Tumor necrosis factor
NI
Non-inferiority
NVR
Dutch Society for Rheumatology (in Dutch: Nederlandse Vereniging voor Reumatologie)
SPC
Summary of Product Characteristics (in Dutch: officiële productinfomatie IB1-tekst)
IB
Investigator’s Brochure
METC
Medical Ethical Testing Committee (in Dutch: Medisch Ethische Toetsingscommissie)
RA
Rheumatoid arthritis
SC
Subcutaneous
CRP
C-reactive protein
AE
Adverse Event
SAE
Serious Adverse Event
HR-QOL
Health related quality of life
QOL
Quality of life
EDC
Electronic data capture
CRF
Case report form
PROs
Patient Reported Outcomes
NRS
Numeric rating scale
HAQ-DI
Health Assessment Questionnaire Disability Index
SF-36
Short form-36
WPAI 18
Work productivity and activity impairment questionnaire
Sobi
Swedish Orphan Biovitrum Ltd
IMPD
Investigational Medicinal Product Dossier
DSMB
Data Safety Monitoring Board
SUSAR
Suspected Unexpected Serious Adverse Reaction
ITT
Intent-to-treat
PP
Per-protocol
CI
Confidence interval
QALDs
Quality adjusted life days
ICUR
Incremental cost-utility ratio
WMO
Medical Research Involving Human Subjects Act (in Dutch: Wet Medisch
Wetenschappeljik Onderzoek)
Dutch Personal Data Protection Act (in Dutch: de Wet bescherming persoonsgegevens)
Wbp
7
Research Protocol NL52526.044.15 / ATTACG
Summary
Background: Gout is a common form of inflammatory arthropathy, with hyperuricemia being the
predominant risk factor. The close relationship between gout and hyperuricemia has led to treatment
strategies wherein both the acute gout flare and hyperuricemia are targeted simultaneously. Currently
available treatment options for gout flares (colchicine, corticosteroids and non-steroidal antiinflammatory drugs; referred to as standard of care (SoC)) are frequently contra-indicated or poorly
tolerated by gout patients due to presence of significant multi-morbidity. Anakinra (Kineret) is an IL1 receptor antagonist presently indicated for the treatment of rheumatoid arthritis (RA) and CryopyrinAssociated Periodic Syndromes. At present, anakinra has been studied in a handful of case series and
small open label studies for its clinical efficacy and safety in acute gout.
Objective: To demonstrate non-inferiority (NI) of anakinra compared with the SoC in the treatment of
acute gout flares. Also, to compare the safety and cost per quality-adjusted life day between anakinra
and SoC and to compare the 3 and 12 months clinical outcome of patients initially treated with
anakinra versus SoC and starting ULT.
Study design: A 3 month multi-center randomized, double (dummy)-blinded, placebo controlled NI
trial, followed by a 9 month open label follow-up study.
Study population: 200 patients with an acute gout flare.
Intervention: Patients will be randomized to 5 consecutive days of daily a 100mg injection of anakinra
+ SoC pill placebo or SoC treatment + 5 consecutive days of anakinra injection placebo. SoC treatment
dosage and duration is according to standard procedures. Both arms will receive urate lowering
therapy according to standard procedures.
Main study endpoints: The main study endpoint is the change in patient-reported pain in the index
joint from baseline to the average of pain values at 24, 48 and 72 hours after initiating treatment.
Secondary endpoints include (in-) direct costs, quality of life (QOL), physical functioning, treatment
side effects, changes in joint swelling & tenderness, C-reactive protein (CRP), uric acid level, patient
perceived treatment response and number of recurrent flares.
Burden, risks and benefits: Patients will have to visit the treating rheumatologist at day 1, 7 and at
month 3 during the study period. At 6 time points over the course of the study patients will have to fill
in a survey questionnaire. During the first 7 days after starting the study (or by onset of a new gout
attack), patients will additionally be required to fill in a survey on patient reported outcomes,
medication intake and experienced side effects. Main risks associated with using anakinra are the
possible physical discomfort of subcutaneous (SC) treatment injections, headache, local (skin) injection
site reaction, serious (respiratory or skin) reactions, neutropenia or/and allergic reactions. Relapse of
a gout flare might occur sooner in patients receiving anakinra or prednisolone compared to patients
receiving prophylactics. The potential risks and concerns associated with this study are managed due
to strict inclusion and exclusion criteria and the establishment of a Data Safety Monitoring Board
(DSMB) and through active safety monitoring. Any remaining risks are considered acceptable since the
risks are not considered severe or life threatening.
8
Research Protocol NL52526.044.15 / ATTACG
1.
Introduction and Rationale
Gout is a common form of inflammatory arthropathy most frequently seen in men and in women
primarily after menopause (1-3). Studies in various geographic locations have shown the prevalence
of gout to be increasing over time, which is frequently attributed to the increasing longevity of the
population and the accumulation of gout risk factors in older age (1, 4-9). Individuals with gout often
present with multiple comorbid conditions, including metabolic syndrome (including hypertension,
diabetes mellitus and obesity), cardiovascular disease and kidney disease (3, 4, 10). Hyperuricemia is
the predominant risk factor for gout and possibly also for many of its most common comorbidities (1).
When left untreated, elevated serum uric acid levels can lead to precipitation of monosodium urate
(MSU) crystals in and around the joints, initiating and stimulating a local inflammatory response.
Although many individuals with chronic hyperuricemia remain asymptomatic, the risk for gout is
greater than when serum uric acid levels are kept within the clinical desired range (0.30 - 0.35 mmol/L).
The clinical manifestation of an acute gout flare is recognized for causing excruciating pain. It can have
its onset in any joint in the body, however, primarily the lower joints in the legs are affected.
The close relationship between gout and hyperuricemia has led to treatment strategies wherein both
the acute gout flare and hyperuricemia are targeted simultaneously (11-13). Three standard options
are available to treat pain and inflammation associated with acute gout, including colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids1. In the Netherlands, allopurinol,
febuxostat and benzbromaron are currently available for the treatment of hyperuricemia by
normalizing uric acid levels in the body, also referred to as urate lowering therapy (ULT). Reduction of
serum uric acid levels following initiation of ULT may induce acute gout flares. To prevent the onset of
these flares, NSAIDS and colchicine are, additionally, recommended as prophylactics agents when
initiating ULT (14-18). Although gout is a well understood rheumatic disease, currently available
treatment options are frequently contra-indicated or poorly tolerated by gout patients, which
frequently presents in the presence of significant multi-morbidity.
Since the discovery of the inflammasome, the crucial role of interleukin (IL) - 1 in initiating and
maintaining gouty inflammation has become well recognized (3, 19). Precipitated MSU crystals at
inflamed joint sites get phagocytized by macrophages or monocytes, leading to intracellular activation
of the NALP3 inflammasome. This system subsequently activates caspase-1, promoting the maturation
of Pro-IL-1β and extracellular excretion of pro-inflammatory IL-1β (19, 20). Secreted IL-1β then binds
to the IL-1 receptor on local endothelial cells and macrophages, signaling them to produce further proinflammatory cytokines and chemokines, including tumor necrosis factor (TNF)-α, IL-6, and neutrophil
chemo attractants (21). These amplify the inflammatory response, attracting other inflammatory cells,
including neutrophils, into the area.
For complex gout patients presenting with multiple comorbidities, IL-1 antagonists may be of great
significance. In 2013, the European Medicines Agency approved the medicinal product canakinumab,
a fully human monoclonal anti-human IL-1β antibody, for the treatment of acute gout flares. Due to
very high costs per treatment, this agent is reimbursed only for patients with frequent gout flares (>2
per year) who cannot tolerate any of the three standard treatments, to a maximum of 2.5 Million euros
per year in the Netherlands.
1
Throughout the entire protocol these standard treatment options, colchicine, NSAIDs and
corticosteroids, will be referred to as standard of care (SoC)
9
Research Protocol NL52526.044.15 / ATTACG
Anakinra (Kineret) is a DNA recombinant IL-1 receptor antagonist currently registered for the
treatment of rheumatoid arthritis and Cryopyrin-Associated Periodic Syndromes. It acts by
competitively inhibiting the binding of IL-1α and IL-1β to IL-1 type I receptors, causing the biological
activity of these interleukins to be neutralized. The clinical efficacy and safety of anakinra in acute gout
have been investigated and reported on in a few case series or small open label studies (22-36).
Although these studies provide a proof of concept for the plausibility and clinical importance of
anakinra as a treatment option for acute gout, no large scale clinical trial has yet been performed. The
primary goal of the proposed study is to demonstrate the non-inferiority (NI) of anakinra versus
treatment as usual in patients with acute gout. Secondary goals are to compare the cost-effectiveness
of anakinra to treatment as usual, to evaluate the safety of anakinra and to compare the 3 and 12
months clinical outcome of gout patients initially treated with anakinra or treatment as usual starting
ULT.
2.
Study Aims
Primary objective
To demonstrate the NI of anakinra compared with the SoC in the treatment of acute gout flares.
Secondary objectives
To compare the cost per quality-adjusted life day between anakinra and SoC.
To evaluate the safety of anakinra in the treatment of acute gout flares.
To compare the 3 and 12 months clinical outcome of patients initially treated with anakinra versus
SoC and starting ULT.
10
Research Protocol NL52526.044.15 / ATTACG
3.
Study Design
Duration and design
The total study duration is 12 months. The initial 3 month study is a multi-center randomized, double
(dummy)-blinded, placebo controlled NI trial, followed by a 9 month open label extension study.
200 patients with crystal proven acute gout will be randomly allocated in the ratio 1:1 to either 1) 5
consecutive days of 100 mg daily anakinra injection and SoC pill placebo or 2) one of the SoC treatment
options and 5 consecutive days of 100 mg anakinra injection placebo. SoC treatment allocation, dosage
and duration are in line with the national guidelines for gout setup by the Dutch Society of
Rheumatology (Dutch: Nederlandse Vereniging voor Reumatologie, NVR) (16). In line with these
guidelines, when tolerable, patients will be appointed SoC treatment with colchicine or NSAID which
will then be continued prophylactically for 90 days when initiating ULT. Patients in both arms will also
receive ULT according to recommendations as stated in the national guidelines for gout by the NVR
(16).
Multi-center research
Subjects will be included into the study by rheumatologists working in different medical centers in the
Netherlands. Between 4-8 centers will participate in this study. General practitioners in the region of
the participating medical centers will be informed and asked to refer patients with suspected gout to
the closest study center.
Coordinating pharmacy
The following pharmacy will function as pharmacy for the production, labelling and distribution of
study medicines in this study:
Slotervaart Hospital
Department of Pharmacy & Pharmacology
Louwesweg 6
1066 EC Amsterdam, the Netherlands
11
Research Protocol NL52526.044.15 / ATTACG
4.
Study Population
Population
The study population will include both male and female patients with an acute gout flare.
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:



At least 18 years of age
Signed written informed consent
Identification of intracellular MSU crystals in primary joint through aspiration of joint
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from participation in this
study in case of:

Absolute contra-indication for all available types of ULT (allopurinol, febuxostat and
benzbromaron)
Contra-indications allopurinol: Hypersensitivity to the active substance or to any of the
excipients (see for the excipients the official SPC for the brand given).
Contra-indications febuxostat: Hypersensitivity to the active substance or to any of the
excipients (see for the excipients the official SPC for the brand given).
Contra-indications benzbromaron: Hypersensitivity to the active substance or to any of the
excipients (see for the excipients the official SPC for the brand given). Patients with known liver
disease. Concomitant use of hepatotoxic drugs, particularly antituberculosis agents. Hepatic
porphyia. Severe renal impairment (clearance < 30 ml/min.). Patients with secretion of urate
higher than 700 mg/24 hours (= 4.2 mmol/24 hour). Urolithiasis. Acute gout flare

Absolute contra-indication for anakinra
Contra-indications anakinra: Hypersensitivity to the active substance or to any of the excipients
(citric acid anhydrous, sodium chloride, disodium edetate dihydrate, polysorbate 80, sodium
hydroxide, water for injections) or to E. coli derived proteins. Kineret must not be used in
patients with severe renal impairment (creatinine clearance rate < 30 ml/minute). Kineret
treatment must not be initiated in patients with neutropenia (absolute neutrophil count <1.5 x
109 /l).


Presence of liver disease that according to the treating physician precludes participation
in the study
Absolute contra-indication for all three of the possible SoC treatments (colchicine,
naproxen, prednisolon)
Contra-indications colchicine: Hypersensitivity to the active substance or to any of the
excipients (microcrystalline cellulose (E460), lactose, sodium carboxy starch, magnesium
stearate (E470b)). Women of childbearing age, unless effective contraceptive measures are
taken. Colchicine should not be used in patients with severe renal impairment or severe hepatic
impairment.
Contra-indications naproxen: Hypersensitivity to the active substance or to any of the
excipients (potato starch, lactose, hydroxypropyl cellulose (200 CP), magnesium stearate,
colloidal anhydrous silicon dioxide). Naproxen is contra-indicated in patients who have
12
Research Protocol NL52526.044.15 / ATTACG
previously shown allergic reactions (e.g. asthma, rhinitis or urticaria) in response to
acetylsalicylic acid or other prostaglandin-synthesis inhibitors. Severe anaphylactoid reactions
have been reported in these patients. In principle, naproxen must not be administered to
patients with gastrointestinal ulcerations, congestive gastritis or atrophic gastritis,
gastrointestinal bleeding or other bleeding such as cerebrovascular bleeding. Severe renal
impairment.
Contra-indications prednisolon: Hypersensitivity to the active substance or to any of the
excipients (lactose, magnesium stearate (E470b), silicon dioxide (E551), potato starch,
pregelatinized potato starch, sodium (potato) starch glycolate, magnesium stearate (E572),
erythrosine (E127)). Gastric and duodenal ulcers. Acute infectious processes, particularly viral
infections and systemic fungal infections. Tropical worm infections. Administration after
vaccination with a live attenuated virus. Ocular herpes simplex.









Known history of allergy or sensitivity to latex
Current use of any ULT (ULT therapies are allopurinol, febuxostat and benzbromaron)
Concurrent use of other IL-1 agents (to this category belong: canakinumab and rilonacept)
Patient reports no to mild gout related pain
Pregnancy or lactation
Women who are planning on becoming pregnant within the study period (12 months)
Patients with active or recurrent bacterial, fungal or viral infection
Patients using TNF inhibitors (to this category belong: Certolizumab, Golimumab,
Adalimumab, Etanercept, Infliximab)
Patient has insufficient knowledge of the Dutch language for completing questionnaires
independently
13
Research Protocol NL52526.044.15 / ATTACG
5.
Treatment of subjects
Investigational treatment
Patients allocated to the investigational treatment group will receive Kineret (active substance
anakinra). For specific information regarding the product characteristics, safety, therapeutic
indications, dosage and duration, etcetera, please see Chapter 6: Investigational treatment of this
protocol.
Comparator treatment
Subjects allocated to the active comparator group will receive colchicine, naproxen (NSAIDS) or
prednisolon (systemic corticosteroids). These treatments are standard medicinal products currently
registered for treating acute gouty arthritis. Per specific case, the treating rheumatologist will decide
on the SoC treatment the patient may receive, according to their medical history, contraindications,
intolerances, etcetera. This is in line with the guidelines for gout treatment as setup by the NVR (16).
All the participating centers will receive medication for all three of the SoC treatments, making the
rheumatologists free to choose the best tolerable SoC treatment for the patient. For specific
information (e.g. dosage and duration) on the standard treatments, please see Chapter 7: Noninvestigational treatment of this research protocol.
Non-active placebos
To ensure blinding, patients will receive non-active placebos. Subjects in the investigational anakinra
treatment group will receive a non-active placebo resembling the SoC treatments. Subjects in the
comparator group will receive a non-active anakinra injection placebo (NaCl 0.9%, 0.67 ml) resembling
the anakinra treatment injection. For details on the blinding of study medication see Chapter 8:
Methods, section Randomization, Blinding and treatment allocation of this research protocol.
Urate lowering therapy (ULT)
All subjects included in either treatment arm will start ULT at baseline. ULT is part of standard
prophylaxis in the treatment of recurrent acute gout flares according to the NVR treatment guidelines
for gout (16). When tolerable, Patients will be appointed ULT with allopurinol When allopurinol cannot
be tolerated, alternatively benzbromaron or febuxostat will be appointed. Please see Chapter 7: Noninvestigational treatment of this research protocol for further details.
Rescue Medication
No rescue medication will be prescribed during the first 7 days after starting the study (baseline – day
7). Patients may use over the counter medicines as NSAIDs and acetaminophen during this time.
Patients will be asked to report the use of any over the counter medicines, as well as other medication
in the patient flare diary. During the rest of the study period, patients can use over the counter
medication and will be asked to rapport the use in the flare diary during the occurrence of refractory
gout attacks.
14
Research Protocol NL52526.044.15 / ATTACG
Refractory gout attack
Patients will return to their treating rheumatologist 7 days after starting the study medication for their
initial acute gout flare. In case of an ongoing or new gout flare between day 7 until the end of the
study, the treating rheumatologist will decide on the gout treatment to give the patient. Treatment
options will be according to standard clinical care. Anakinra treatment will not be available as
treatment option for refractory gout attacks. Patients will be instructed to contact their treating
rheumatologist in case a new gout flare arises during the study period. The treating rheumatologist
can, together with the sponsor, decide if breaking the treatment randomization code is needed in
order to provide the best optimal care for the patient.
15
Research Protocol NL52526.044.15 / ATTACG
6.
Investigational treatment
For a detailed description of the investigational product characteristics, therapeutic indications,
dosages, pharmaceutical properties, side effects, etcetera, please see the Summary of Product
Characteristics (SPC) and Investigator’s Brochure (IB) submitted as part of the dossier for the Medical
Ethical Testing Committee (in Dutch: Medisch Ethische Toetsingscommissie, METC). A short summary
of general information regarding anakinra and studies with anakinra for gout is given below.
Name and descriptive
Kineret contains the active substance anakinra. It is a recombinant, nonglycosylated form of the
human IL-1 receptor antagonist (r-metHuIL-1ra). Besides the inclusion of a single methionine residue
at its amino terminus, it is identical to the naturally present human IL-1 receptor antagonist. Anakinra
is produced by means of recombinant DNA technology in Escherichia coli cells. Currently, Kineret is
registered for treating adults with signs and symptoms of rheumatoid arthritis (RA) and for cryopyrinassociated periodic syndromes.
Summary of findings from pre-clinical studies
Pre-clinical information regarding anakinra is listed in the SPC. One animal study has been done with
anakinra and gout by So et al. 2007 (34). The effectiveness of IL-1 inhibition in relieving inflammatory
manifestations associated with gout was studied in in-vivo MSU crystal-induced inflammation BALB/c
mice. The mice were given anakinra injections, anti-IL-1R1 monoclonal antibodies or anti-TNF
monoclonal antibodies and the level of neutrophil recruitment was determined. Both anakinra and the
anti-IL-1R1 monoclonal antibody showed comparable inhibitory effects on neutrophil recruitment. The
results were statistically significant compared to a positive MSU control.
Summary of findings from clinical studies
In total, the clinical effectiveness of anakinra in gout has been documented in 15 case reports and/or
series and 1 small open-label study (updated 20 March 2015) (22-37). The patients included in these
studies were all complex gouty arthritis patients with severe comorbidities and/or intolerance to
conventional therapies. Treatment with anakinra was, therefore, used as an alternative agent. In the
15 case reports and/or series, anakinra demonstrated to rapidly and effectively alleviate the pain
associated with gout in the majority of the patients. Dosage regimes differed between patients, with
some taking 100 mg anakinra daily for three consecutive days, whilst others took anakinra daily or
every other day for up to six months. In this population, observed side effects included one injection
site reaction, neutropenia in another patient, one case of leukopenia, seven infectious complications
and twice the occurrence of a H1N1 Influenza infection after initiating anakinra therapy. One critically
ill case developed an infectious complication (herpes zoster) one day after completing a 6-day anakinra
treatment, possibly related to the anakinra treatment. One patient developed a postoperative wound
infection, whereby the site was possibly already infected before anakinra treatment was initiated. Four
patients could not discontinue anakinra treatment without getting an acute flare within several days
after stopping. One open-label clinical trial has been documented, including 10 patients taking 100 mg
subcutaneous (SC) anakinra for 3 consecutive days (34). Patients responded rapidly to anakinra, with
the most rapid onset observed within 24 hours. The subjective symptoms of gout were greatly relieved
48 hours after the first injection in all patients. No side effects were observed during the study period,
16
Research Protocol NL52526.044.15 / ATTACG
and there were no infectious complications. Only one patient had a minor flare at one month followup. For anakinra in gout, no randomized-controlled clinical trials have been reported. In general, the
documented studies show the possible efficacy of anakinra for the treatment and rapid relief of acute
gout flares in severe and complex comorbid gout patients, not able to take or tolerate conventional
therapies.
Summary of known and potential risks and benefits
The potential risks associated with using anakinra for the treatment of acute gouty arthritis are:









Physical discomfort of SC treatment injection
Local (skin) injection site reaction (pain, inflammation, erythema, or ecchymoses)
Serious infections (respiratory and skin infections, Influenza infections)
Allergic reaction and anaphylaxis (angioedema, urticarial and pruritus) to anakinra or other
constituents, including latex
Decreased neutrophil count, leading to neutropenia
Drug interaction between ULT and anakinra
Elevated levels of liver enzymes
Gastrointestinal disturbances related to liver disorders (yellow skin and eyes, nausea, loss of
appetite, dark-colored urine, light-colored stools)
Headaches
The potential benefits associated with the use of anakinra for the treatment of acute gout arthritis are
alleviation of inflammation, pain and disease burden.
Description and justification of route of administration and Dosage
Active and placebo Kineret will be administered by SC injection once daily. Each syringe contains
100mg anakinra or non-active anakinra (NaCL 0.9%, 0.67 ml) placebo. The route of administration will
be identical to current standard procedures applied for RA patients. To prevent and avoid discomfort
at the site of injection, it is recommended to change the injection site location regularly. Current
recommendations as listed in the SPC for the method of administration for anakinra, will also be
applicable and followed in this study.
Preparation and labelling of investigational medicinal product
Finished products of anakinra and anakinra placebo injections will be delivered by Swedish Orphan
Biovitrum AB (Sobi) to the coordinating pharmacy before the start of the study. The coordinating
pharmacy is responsible for preparing and re-labeling these medicinal products. During preparation
and labeling of anakinra and anakinra placebos, the coordinating pharmacy will comply with the GMP
guidelines.
Drug accountability
The allocation of anakinra and anakinra placebo to the local pharmacy of each participating sites will
be done under strict supervision of the central coordinating pharmacy and the proper environmental
settings. The study medication will be delivered to, accepted by and stored at the local pharmacy of
each participating site. The nurse/treating rheumatologist is responsible for retrieving these packages
17
Research Protocol NL52526.044.15 / ATTACG
and handing these over to the patient or the patient can retrieve the medication package and return
to the treating rheumatologist/nurse who will further guide the patient. If during the trial any of the
products are not fit for use or are not being used, these will be retoured to the central coordinating
pharmacy and replaced if needed and possible. The treating rheumatologist/nurse should together
with the local pharmacy ensure proper sending of the unusable medication to the coordinating
pharmacy in case of retouring products.
18
Research Protocol NL52526.044.15 / ATTACG
7.
Non-investigational treatment
Name and description of available SoC treatments
Colchicine
Colchicine is indicated for treating acute gouty arthritis in patients who cannot tolerate, or who have
contra-indications for, NSAIDs. It is also used as a prophylaxis for gout flares when initiating ULT in
patients who cannot tolerate, or who have contra-indications for, NSAIDs.
NSAID, naproxen
Therapeutic indications for naproxen include many inflammatory musculoskeletal diseases, including
gouty arthritis. Naproxen is a prostaglandin synthetase inhibitor and belongs to the group of NSAIDs,
which are used to control pain and inflammation.
Systemic corticosteroid, prednisolon
Prednisolon is used to treat rheumatic conditions and other bodily disorders. Prednisolon is a
corticosteroid which primarily acts as a glucocorticosteroid. The therapeutic effect of
glucocorticosteroids is mostly through two mechanisms; an anti-inflammatory or immunosuppressive
(anti-allergic) mechanism.
Urate Lowering Therapy
Different ULT treatments are available; allopurinol, febuxostat and benzbromaron. All are aimed at
lowering the urate/uric acid levels in the blood serum, however, the mechanism of action differs
between the three. Allopurinol and febuxostat work by inhibiting the action of the enzyme xanthine
oxidase, which plays a role by the conversion from hypoxanthine into uric acid. Benzbromaron acts as
a uricosuric agent, which causes the excretion of uric acid in the urine to be increased.
Non-active SoC placebos
Oral SoC placebo medication will be provided in capsules, identical in size, shape color and appearance
to the active SoC treatment. For details about the blinding of study medication, see Chapter 8:
Methods, section Randomization, Blinding and treatment allocation.
Dosage and method of administration
For all SoC treatments and placebos and ULT treatments, the dosage, duration and method of
administration will be in line with the Gout Guidelines of the NVR and standard care procedures (16).
For colchicine (placebo) this is 3 daily dosages of 0.5 mg for 90 days, for naproxen (placebo) twice a
day 500 mg for 90 days and for prednisolone (placebo) 35 mg daily dosage for 5 days. Colchicine and
naproxen will be continued for 90 days as these are given as prophylaxes when initiating ULT. Patients
receiving naproxen will be prescribed antacids in line with the standard procedure when receiving
NSAID for longer periods of time. For ULT treatment the first choice will be allopurinol 100 mg daily for
1 week followed by 300 mg. Alternatively benzbromaron or febuxostat will be used. Dosage will be
adjusted according to treating to target of urate serum concentration below 0.30 mmol/L. ULT will be
initiated at baseline.
19
Research Protocol NL52526.044.15 / ATTACG
Preparation and labelling of non-investigational medicinal product
The central coordinating pharmacy will ensure the proper number of SoC treatments and placebos will
be acquired before the start of the study. During the preparation and labeling of SoC treatment and
SoC placebos the coordinating pharmacy will comply with the GMP guidelines.
Drug accountability
The allocation of SoC and SoC placebo to the local pharmacy of each participating sites will be done
under strict supervision of the central coordinating pharmacy and the proper environmental settings.
The study medication will be delivered to, accepted by and stored at the local pharmacy of each
participating site. The nurse/treating rheumatologist is responsible for retrieving these packages and
handing these over to the patient or the patient can retrieve the medication package and return to the
treating rheumatologist/nurse who will further guide the patient. If during the trial any of the products
are not fit for use or are not being used, these will be retoured to the central coordinating pharmacy
and replaced if needed and possible. The treating rheumatologist/nurse should together with the local
pharmacy ensure proper sending of the unusable medication to the coordinating pharmacy in case of
retouring products.
20
Research Protocol NL52526.044.15 / ATTACG
8.
Methods
Study endpoints
Primary endpoint
 Change in patient-reported pain in the index joint from baseline to the average of pain values
at 24, 48 and 72 hours
Secondary endpoints of 3 month randomized controlled trial















Time to 50% reduction in pain in the primary affected joint
Time to remission of pain
Time to first reoccurrence of flare
number of new flares
Decrease of primary joint swelling according to patient across day 2-5
Decrease of primary joint tenderness according to patient across day 2-5
Decrease in C-reactive protein (CRP) levels after 7 days of treatment
Decrease of serum uric acid concentration after 3 months
Treatment response according to patient across day 2 -7
% dropout due to adverse events (AE)
% dropout due to serious adverse events (SAE)
physical function
Health related quality of life (HR-QOL)
Experienced side effects
Direct and indirect costs
Secondary endpoints of 9 month open label study extension








Time to first reoccurrence of flare
number of new flares
% patients starting with canakinumab treatment
% patients with serum uric acid concentration ≤ 0.36 mmol/l
Physical function
HR-QOL
Experienced side effects
Direct and indirect costs
Data collection
All data will be collected using an electronic case report form (CRF). The electronic data capture (EDC)
system used is ROMA2, currently also being used for different clinical trials within the field of
rheumatology. Within ROMA2 a study specific template will be developed. All data will be collected
and entered by the participating sites directly into the EDC system. The sites will be fully trained for
using the EDC system. The data which is to be collected from the patients directly (e.g. questionnaires)
will also be collected using the EDC system. The data will be saved in a secure database.
21
Research Protocol NL52526.044.15 / ATTACG
Patient data collection and follow-up will take place at baseline, days 2-7, month 3 and thereafter at
month 6, 9 and 12. In case of recurrence of gout flares, patients are asked to contact the treating
rheumatologist and to keep a flare diary for 7 consecutive days. Treating rheumatologists are asked to
document any side effects, AE and SAE in the CRF. Decisions regarding treatment of recurrent flares
are at the discretion of the attending physician and the patient. See schedule below for follow-up
moments:
Table 1. Patient follow-up scheme.
Baseline
(day 1)
Eligibility
criteria (e.g.
aspiration of
joint fluid)
Informed
consent
Day
2
Day
3
Day
4
Day
5
Day
6
Day
7
Month
3
followup
(month
6, 9)
Study
end
(month
12)
X
X
Demographics
X
Patient medical
status
X
Serum uric acid
X
X
X
X*
X*
CRP level
X
X
X
X*
X*
Flare diary
X
Physical
functioning
X
X
X
X
X
HR-QOL
X
X
X
X
X
Work
productivity &
health care
volumes
X
X
X
X
X
X
X
AE and SAE
Onset
new
flare
X
X
X
X
X
X
X
X
Study dropout/
X**
completion
* Laboratory results that become available during the routine clinical care during the course of the study will be
collected.
**Patients lost during follow-up will be recorded in the CRF
22
Research Protocol NL52526.044.15 / ATTACG
Data collection tools
Patient numbering
Each patient is identified by a unique 5 character patient identification number, assigned by the EDC
system. The first two numbers will index the center number at which the patient is included and the
final three numbers index the patient’s order of inclusion at the study site.
Baseline characteristics
At baseline, demographic characteristics including sex, age, weight, length, blood pressure will be
collected. A patient medical status including gout status, comorbidities and other medication usage
will also be obtained at baseline and updated throughout the study. Whether the patient entered the
study through primary or secondary health care will also be noted. See Appendix I for the specific CRF
information gathered by the treating rheumatologist.
Uric acid and CRP measurement
At baseline, serum uric acid and CRP level will be determined. During the course of the study, CRP and
serum uric acid levels will be recorded according to the data collection scheme in Table 1. Whenever
laboratory results on CRP levels and serum uric acid levels become available during routine/regular
clinical care, these results will also be collected during the course of this study.
Patient flare diary
A digital (or if needed pen and paper) flare diary will be filled in at home during the occurrence of acute
gout flares for 7 consecutive days upon flare onset. The following will be recorded daily: pain intensity,
swelling, tenderness, treatment response, global assessment of overall wellbeing, study medication
intake, other medication intake and experienced side effects. The side effects will be reported to the
treating rheumatologist, who will register these effects along with potential AE and SAE. Study
medication intake will be noted for determining the compliance of patients to the study medication.
See Appendix II for the patient flare diary.
Patient reported outcomes (PROs)
PROs will be measured using standardized instruments available, at baseline and during follow-up
according to the data collection scheme in Table 1. PROs are made available to the patients on the
computer and if needed a paper and pencil version will be available as well. The patient reported
domains measured are pain intensity, amount of swelling, tenderness of joint, treatment response,
physical functioning, health related quality of life, work productivity. See for all PROs questionnaires
and flare diary Appendix III and II. Below a specific explanation of the specific tool used to measure
each specific PRO:

Pain intensity: Pain intensity at the primary joint during treatment follow-up time will be
assessed using a 5-point Likert scale (1 = none; 2 = mild; 3 = moderate; 4 = severe; 5 = extreme)
and a 100mm visual analog scale (0 = no pain, 100 = worst imaginable pain). Also a numeric
rating scale (NRS) will be used to measure pain intensity (0 = no pain at all until 10 = worst
imaginable pain).
23
Research Protocol NL52526.044.15 / ATTACG







Swelling: The amount of swelling of the primary joint will be measured using a 5-point Likert
scale (1 = none; 2 = mild; 3 = moderate; 4 = severe; 5 = extreme).
Tenderness: The tenderness of the primary joint will be determined using 5-point Likert scale
(1 = none; 2 = mild; 3 = moderate; 4 = severe; 5 = extreme).
Treatment response: Treatment response according to the patient will be assessed using a 9point Likert scale (1=fully disappeared; 2=very much improved; 3=much improved; 4=slightly
improved; 5=no changes; 6=slightly worse; 7=much worse; 8=very much worse; 9=not
applicable).
Global assessment of overall wellbeing: The global assessment of overall wellbeing will be
assessed using a 10 point NRS (0 = worst imaginable health until 10 = best imaginable
wellbeing).
Physical functioning: Disability will be assessed using the Stanford Health Assessment
Questionnaire Disability Index (HAQ-DI) (38). HAQ-DI assesses disability using 20 questions
regarding dressing and grooming, arising, eating, walking, hygiene, reach, grip and activities.
Individual item scores can be adjusted for the use of aids or help from others in completing
the activities referred to in the item. Category scores represent the highest individual item
score in each category and an overall disability score is obtained by averaging the category
scores. Higher scores indicated more disability.
HR-QOL: HR-QOL will be assessed using the medical outcomes survey short form 36 (SF-36)
(39). The SF-36 assesses the 8 HR-QOL domains of: bodily pain, physical role function, physical
function, general health, emotional role function, vitality, and social function. For each domain
a summary score is obtained ranging from 0-100, with higher scores representing better
health.
Work productivity and health care volumes: Work productivity will be assessed using the Work
Productivity and Activity Impairment Questionnaire (WPAI) (40). The WPAI includes questions
about employment: time lost from work, reduced productivity at work and reduced
productivity while engaged in regular activities in the previous week. Patients will also be asked
to report the volume of hospital related care using a standardized questionnaire.
Side effects , AE and SAE
Side effects, AEs and SAEs will be obtained during follow-up according to the data collection scheme
in Table 1. Patients are asked to report any side effects experienced in the daily flare diary and
subsequently report this to their treating rheumatologist at follow-up moments. At each visit
rheumatologists will be requested to state whether or not patients experience specific side effects
potentially related to IL-1 suppression including: serious infections, malignancy, opportunistic
infections, drug induced liver injury, major adverse cardiovascular events, severe injection site
reactions, AEs related to immunogenicity/allergincity, worsening uric acid levels, disorders of
lipoprotein metabolism, worsening kidney function, potential vaccine interactions and pregnancy. All
AE – including SAE irrespective of causality and safety endpoints (where relevant) – will be collected
and recorded in the CRF, irrespective of causal association. If an AE or SAE occurs in between followup moments this should be reported to the treating rheumatologist and be reported in the CRF.
Patients can report side effects through the online web portal. For details regarding the safety
monitoring during this study, see Chapter 9: Safety reporting, section Safety monitoring of this
protocol.
24
Research Protocol NL52526.044.15 / ATTACG
Direct and indirect costs
The direct and indirect costs will be calculated from the work productivity and health care volumes
questionnaire filled in by the patient. Volumes of hospital related care, i.e. consultations with the
rheumatologist and the rheumatology nurse, hospital admissions, as well as medication use (exact
dose of gout medication and administration period) will be prospectively registered in the electronic
CRF. Direct costs will be calculated by multiplying volumes of care by their respective costs. The
standard cost prices from the 2016Dutch Guideline for Cost Analyses will be used for hospital related
care. Cost prices for medication will be retrieved from the 2016 Dutch national tariff list provided by
the Dutch Board of Health Insurances.
Study drop-out or completion
Information about patients that decide to stop with the study prematurely will be documented in the
CRF. In the CRF will be noted when a patient has completed the study.
Distribution of medicines to participating centers
The distribution of the study medication to each of the participating sites will be done in 2 shifts. The
first shift will consist out of small batches and aims to determine the speed of inclusion at each
participating site. Depending on these findings, the study medication will be allocated a second time.
The central coordinating pharmacy is responsible for proper distribution of the study medication to
each site, including the proper environmental settings (e.g. temperature). The study medication will
be delivered to and accepted by the local pharmacy of each participating site. The study medication
will be stored at the local pharmacy of the participating site.
Randomization, blinding and treatment allocation
Patients will be asked to participate in this study, be given additional information and asked informed
consent by their treating rheumatologist. At times, a research nurse can give additional information or
ask for patient informed consent when asked to do so by the rheumatologist. When patients have
signed the written informed consent, the treating rheumatologist will give the patient a prescription
wherein states which one of the three SoC treatments the patient can be given. As the packages are
stored at the local pharmacy, the patient self or the nurse/treating rheumatologist can retrieve these
packages and hand it over to the patient. Depending on the tolerable SoC treatment, patients will be
appointed randomly to either the anakinra treatment or the patients’ tolerable SoC treatment. The
randomization is based on a previous computer-generated randomization list (anakinra or SoC) per
SoC treatment. No stratification will be carried out. When the patient has received the medication
package he/she will be instructed by the nurse on how to properly inject themselves with the syringe
as well as other baseline characteristics will be gathered. The research nurse will register the new
patient in the EDC, which will assign the patient an automated unique 5 character patient identification
number. See Chapter 8: Methods, section Patient numbering for details regarding this number. The
treatment packages will also each be identified by a number, which will be linked to the patient
identification number in the EDC. Each treatment package will contain either anakinra injections along
with the tolerable SoC placebo medication, or anakinra placebo injections with the tolerable active SoC
treatment. Oral SoC medication and placebos will be provided in capsules, identical in size, shape color
and appearance. For details on SoC treatments and placebos see the Investigational Medicinal Product
25
Research Protocol NL52526.044.15 / ATTACG
Dossier (IMPD) submitted as part of the dossier for the METC. Anakinra and anakinra placebo are a
solution for injection, available in pre-filled syringes ready for SC use. Treating rheumatologists/nurses
do not have access to the randomization (treatment) code except in case of a SAE and/or SUSAR. In
this case, the code may be broken only in circumstances when knowledge of the study medication is
essential for treating the patient. In case of a SAE or SUSARs, the local responsible investigator will
contact the sponsor directly (see Chapter 9: Safety Reporting, section SAE reporting). The sponsor and
local head investigator will together decide if the code needs to be broken. If needed, the sponsor may
contact the Data Safety Monitoring Board (DSMB) for further advice regarding the specific matter.
Withdrawal of individual subjects from the study
Subjects are free to quit the study at any time for any reason if they wish to do so without any further
consequences to their medical treatment. The treating rheumatologist and/or study investigator can
decide to withdraw a subject from the study for urgent medical reasons or because of serious protocol
violation.
Replacement of individual subjects after withdrawal from the study
If subjects are withdrawn from the study, no replacement of the subject will occur. In the total sample
size calculation a dropout rate of 10-13% was included.
Follow-up of subjects withdrawn from study
The data retrieved from subjects who were withdrawn from the study will be used for data analyses.
Follow-up of subjects withdrawn from treatment
Patients who will be withdrawn form treatment due to intolerable side effects or due to lack of efficacy,
will be instructed by their physician to continue to fill in questionnaires until the end of the study.
Premature termination of the study
The sponsor and/or DSMB may decide to prematurely end the study when feels the health of the
subjects are put at jeopardy. For details on the DSMB see Chapter 9: DSMB of this protocol.
26
Research Protocol NL52526.044.15 / ATTACG
9.
Safety reporting
Section 10 WMO event
In accordance to section 10, subsection 1, of the WMO, the investigator will inform the subjects and
the reviewing accredited METC if anything occurs, on the basis of which it appears that the
disadvantages of participation may be significantly greater than was foreseen in the research proposal.
The study will be suspended pending further review by the accredited METC, except insofar as
suspension would jeopardise the subjects’ health. The investigator will take care that all subjects are
kept informed.
Safety monitoring
Patients will be informed to contact their treating rheumatologist when severe side effects (e.g.
infections) occur and asked to report side effects during the entire study period directly to their
treating rheumatologist and by reporting this through the web portal and/or in the flare diary during
gout attacks. All AE/SAE will be collected and recorded in the electronic CRF and database, irrespective
of causal association. All AE/SAE directly observed or reported by the patient or caregiver to the
treating rheumatologist or other site personnel, from the time of prescribing anakinra or SoC and
entering this study, should be evaluated by the site and assessed for seriousness and relatedness to
anakinra or SoC, as defined below in the section ‘AE reporting’.
AE reporting
An AE is the appearance or worsening of any undesirable sign, symptom, or medical condition
occurring after starting anakinra or SoC even if the event is not considered to be related to anakinra or
SoC. Medical conditions/diseases present before starting anakinra or SoC are only considered AEs if
they worsen after starting anakinra or SoC. Abnormal laboratory values or test results constitute AEs
only if they induce clinical signs or symptoms, are considered clinically significant, or require therapy.
All AE reported spontaneously by the subject or observed by the investigator or the staff are to be
recorded regardless of whether considered related to anakinra or SoC. In addition, all reports of the
following special scenarios are considered an AE irrespective if a clinical event has occurred:
 Drug-drug or drug-food interaction
 Drug exposure during pregnancy
 Lack of effectiveness
 Overdose
 Drug abuse and misuse
 Drug maladministration or accidental exposure
 Dispensing errors / medication errors
 Off-label use
 Withdrawal or rebound symptoms
All AEs recorded on the adverse event CRF in the EDC system should include the following information:
 The severity grade
 Relationship to medicinal product being studied
 Duration (start and end date, if applicable)
27
Research Protocol NL52526.044.15 / ATTACG


Whether it constitutes a SAE (if so, follow rules for SAE reporting)
Whether the AE is treated
SAE reporting
A SAE is any untoward medical occurrence or effect that:






Results in death;
Is life threatening (at the time of the event);
Requires hospitalisation or prolongation of existing inpatients’ hospitalisation;
Results in persistent or significant disability or incapacity;
Is a congenital anomaly or birth defect;
Any other important medical event that may not result in death, be life threatening, or require
hospitalization, may be considered a serious adverse event when, based upon appropriate
medical judgement, the event may jeopardize the subject or may require an intervention to
prevent one of the outcomes listed above.
Information about all SAEs (and SUSAR, see below) is collected and recorded on the adverse event CRF
in the EDC system and should include information as mentioned in the previous subsection AE
Reporting.
In case a (S)AE arises (or SUSAR, see below) occurs within the first 30 days after start of the study, the
responsible investigator at that participating site should report this to the sponsor directly (within 24
hours; email: m.vandelaar@mst.nl / tel: 053 – 487 2450). The sponsor will report the SAEs (or SUSAR)
through the web portal ToetsingOnline to the accredited METC that approved the protocol, within 15
days after the sponsor has first knowledge of the SAE. SAEs (or SUSARs) that result in death or are life
threatening should be reported expedited. The expedited reporting will occur not later than 7 days
after the responsible investigator has first knowledge of the adverse event. This is for a preliminary
report with another 8 days for completion of the full report. After the first 30 days after starting the
study, the occurrence of any (S)AE and/or SUSAR will not need to be reported (expeditely) as
mentioned above, but will need to be summarized in a line listing which will be made available to the
accrediting METC periodically.
Documented SAEs (and SUSARs) as a result of anakinra injection during the duration of the trial,
independent of causality, will be reported to Sobi within 24 hours of first awareness. This can be done
by sending an email to the Sobi Drug Safety Department (drugsafety@sobi.com). The sponsor and
investigator shall assist Sobi in obtaining follow-up information for any reported serious adverse
events.
Suspected unexpected serious adverse reactions reporting
Adverse reactions are all untoward and unintended responses to an investigational product related to
any dose administered. Unexpected serious adverse reactions are Suspected unexpected serious
adverse reactions (SUSARs) if the following three conditions are met:
1. the event must be serious;
28
Research Protocol NL52526.044.15 / ATTACG
2. there must be a certain degree of probability that the event is a harmful and an undesirable
reaction to the medicinal product under investigation, regardless of the administered dose;
3. the adverse reaction must be unexpected, that is to say, the nature and severity of the adverse
reaction are not in agreement with the product information as recorded in:
 SPC for an authorised medicinal product;
 Investigator’s Brochure for an unauthorised medicinal product.
When, within the first 30 days after start of the study, the head investigator at a participating centre
has first knowledge of any (S)AE, independent of whether it might be a SUSAR, he/she will report this
immediately to the sponsor (within 24 hours; email: m.vandelaar@mst.nl / tel: 053 – 487 2450). The
sponsor will decide, depending on the assessment of the head investigator, if the (S)AE is a SUSAR. The
recording of SUSARS in the CRF and reporting of SUSARs to Sobi and the METC will be done by the
sponsor and follow the same procedure as for the reporting of SAE (see previous section: SAE
reporting). The expedited reporting of SUSARs through the web portal ToetsingOnline is sufficient as
notification to the competent authority. The reporting of SUSARs occurring 30 days after start of the
study, will be reported in a line listing made available to the accrediting METC periodically.
Follow-up of AE and SAE
All AEs will be followed until they have abated, or until a stable situation has been reached. Depending
on the event, follow up may require additional tests or medical procedures as indicated, and/or
referral to the general physician or a medical specialist. AEs,SAEs and SUSARs need to be reported in
the CRF system till end of study within the Netherlands, as defined in the protocol.
Annual safety report
In addition to the expedited reporting of SUSARs, the sponsor will submit, once a year throughout the
clinical trial, a safety report to the accredited METC and competent authority. The annual safety report
will be combined with the annual progress report. This safety report consists of:
1. A list of all suspected (unexpected or expected) serious adverse reactions, along with an
aggregated summary table of all reported serious adverse reactions, ordered by organ system,
per study;
2. A report concerning the safety of the subjects, consisting of a complete safety analysis and an
evaluation of the balance between the efficacy and the harmfulness of the medicine under
investigation.
Data Safety Monitoring Board
To perform ongoing safety surveillance of the study participants, an independent DSMB will be
established before the first participant starts the study. For further details regarding the DSMB, see
the DSMB charter in Appendix IV.
29
Research Protocol NL52526.044.15 / ATTACG
10.
Data analyses
Populations
Primary efficacy analyses will be performed for both the intention-to-treat (ITT) and per-protocol (PP)
populations. The ITT population will consist of all randomized subjects who have been administered at
least one dose of study medication. The PP population will exclude all subjects in the ITT population
who meet any of the following criteria:
•
•
Have taken any interfering concomitant medications during the first three days of the study.
Have missing data for one or more assessments of the primary outcome.
Primary efficacy analyses
The primary outcome of this study is the difference between treatment arms in change in patientreported pain on a 5-point Likert scale in the index joint from baseline to the average of the patientreported pain values at 24, 48 and 72 hours (referred to hereafter as Δpain). In accordance with FDA,
EMA and consort guidelines, the NI-margin for this study was established after carefully considering
the maximum clinically tolerable loss of efficacy of anakinra compared with SoC and by estimating a
putative placebo effect from historical results of clinical studies in acute gout employing the 5-point
Likert pain scale as the primary outcome (41-44).
Previous NI studies in gout with the 5-point Likert scale have employed a difference of 0.5 points in
favor of the active comparator as a NI margin based on clinical reasoning only (i.e. the maximum
clinically tolerable loss of efficacy) (44-46).
A review of studies identified in a systematic search of the PubMed database revealed that all but one
of the previous clinical studies in acute gout compared different NSAIDs (44-46). No difference in
efficacy was found between treatment arms in any of the studies and mean Δpain ranged from -1.2 to
-1.4 (M=-1.4) in these studies. Although no placebo controlled trials had yet been performed, one
recent study randomized patients to SC rilonacept 320 mg at baseline plus the NSAID indomethacin 50
mg, oral TID for 3 days followed by 25 mg TID for up to 9 days (n = 74); SC placebo at baseline plus oral
indomethacin as above (n = 76); or SC rilonacept 320 mg at baseline plus oral placebo (n = 75)(47). No
significant difference in Δpain was observed between the rilonacept + indomethacin group and the
placebo + indomethacin group. From these results the authors concluded that rilonacept in
combination with indomethacin did not provide additional pain relief over 72 hours relative to
indomethacin alone in patients with acute gout flare. However, significant between group differences
were observed between the rilonacept + placebo group and the rilonacept + indomethacin group (Dif.
Δpain = -0.7, 95% CI = -0.4 -1.0).
Anakinra will be declared non-inferior to SoC in case it can be demonstrated that the difference
between anakinra and SoC does not exceed 0.4 points in favor of SoC on Likert pain. This NI margin
corresponds to the lower bound of the 95% CI for the difference between groups (indomethacin +
rilonacept vs placebo + rilonacept) observed in the study by Terkeltaub et al. 2013 (47). This NI margin
is slightly more stringent than employed in previous NI studies in acute gout and represents a
conservative estimate of the effect of anakinra relative to historical placebo, since the assumed
30
Research Protocol NL52526.044.15 / ATTACG
placebo effect corresponds to the historically observed effect of placebo plus single injection
rilonacept.
The hypotheses tested in this study are:
H0: ΔpainAnakinra - ΔpainSoC > 0.4
Ha: ΔpainAnakinra - ΔpainSoC ≤ 0.4
The study hypotheses will be tested in an analysis of covariance model (ANCOVA) with treatment group
as a fixed factor and baseline pain scores as a covariate. NI of anakinra compared with SoC will be
accepted if the upper bound of the 95% CI around the estimated difference in the primary endpoint
lies to the left of the NI margin of 0.4, both in the ITT analysis and the PP analysis. Non-compliance
may bias ITT analysis towards NI, a sensitivity analysis will be performed where non-compliant patients
will be excluded from the ITT analysis (48). For the purpose of this analysis, patients who report to
have missed 1 or more dosages of anakinra or SoC during the first three days and/or report having
taken any pain-relieving agent during the same period will be considered non-compliant.
In case NI of anakinra compared with SoC has been accepted, a superiority analysis will be performed
on the ITT population. Superiority of anakinra versus SoC will be concluded in case the upper bound of
the 95% CI around ΔpainAnakinra - ΔpainSoC < 0.
Missing Data
It will be assumed that any missing data will occur at random and missing values will be imputed for
the ITT population using multiple imputation by chained equations. The imputation models will be
specified to include the individual pain scores observed at days 1-7 and any available variable that has
a statistical association with the outcome to be imputed or with missingness, as identified in a logistic
regression analysis with missingness as the dependent variable (49). 20 datasets with imputed
plausible values will obtained, with 200 iterations between data sets. Rubin’s rules will be employed
to obtain pooled parameter estimates and their associated standard errors for all analyses. The results
of the analysis of the primary study hypothesis using the pooled results will be compared to the results
obtained on the observed data alone.
Secondary analyses
Secondary efficacy endpoints will be analyzed by specifying a series of linear mixed-effects models with
the endpoint as the dependent variable and time, treatment group and their interaction as fixed
effects. Continuous variables will be summarized with sample size, mean, standard deviation and
range. Frequency counts and percentage of subjects within each category will be provided for
categorical data.
Safety analyses
Safety will be evaluated by tabulations of AE/SAE and will be presented with descriptive statistics at
baseline and follow-up visits for each treatment group.
31
Research Protocol NL52526.044.15 / ATTACG
Cost effectiveness analyses
The primary utility measure of the study is quality adjusted life days (QALDs), and will be calculated
from the SF-36 scores (SF-6D). The incremental cost-utility ratio (ICUR) will be calculated by dividing
the difference in costs by the difference in the QALDs produced by the two groups. The ICUR is
expressed as costs per QALD gained.
Sample size considerations
A standard deviation of 0.94 will be assumed for Δpain, corresponding to the findings of previous studies
(44-47). Furthermore it is assumed that there is no difference in effectiveness between anakinra and
SoC. 87 patients per arm need to be included to be 80% sure that a 97.5 % CI for SoC - Anakinra does
not contain the NI limit of 0.4. Taking a 10-13% drop out rate into account, 100 patients per arm will
be included in the study to ensure sufficient power for the per protocol analyses.
32
Research Protocol NL52526.044.15 / ATTACG
11.
Ethical considerations
Regulatory and ethical compliance
The study will be conducted in accordance with the ethical principles outlined in the Declaration of
Helsinki (version 2013) and the Medical Research Involving Human Subjects Act (in Dutch: Wet
Medisch Wetenschappeljik Onderzoek, WMO 2006)(50).
Recruitment and informed consent procedures
Adequate and complete oral and written information about the nature, purpose(s), risk(s) and
benefit(s) of the study will be made available to potential subjects by the treating
rheumatologist/nurse. The subjects will be informed about the opportunity to ask an independent
physician additional questions and are given a maximum of one day for making a decision. This
relatively short period of time is necessary, given that most gout attacks spontaneously resolve in 1 to
2 weeks. Eligible patients will only be included in the study after providing written (witnessed, where
required by law or regulation), METC approved informed consent. Informed consent must be obtained
before conducting any study procedures. The process of obtaining informed consent should be
documented in the patient source documents. Treating rheumatologists will be provided with an
informed consent form template that complies with the relevant guidelines and regulatory
requirements.
Compensation for injury
Each participating centre has a liability insurance (in Dutch: aansprakelijkheidsverzekering) which is in
accordance with article 7, subsection 9 of the WMO for the participants taking part in the study at that
centre.
The sponsor (linked to Medisch Spectrum Twente, Enschede) has an insurance (in Dutch:
proefpersonenverzekering) which is in accordance with the legal requirements in the Netherlands
(Article 7 WMO and the Measure regarding Compulsory Insurance for Clinical Research in Humans
2015). This insurance provides cover for damage to research subjects through injury or death caused
by the study. The insurance applies to the damage that becomes apparent during the study or within
4 years after the end of the study. All subjects at the different participating centres are covered by the
insurance.
33
Research Protocol NL52526.044.15 / ATTACG
12.
Administrative aspects, Monitoring and Publication
Handling data and documents
Each patient’s data collected for this study will be stored under an assigned unique number. All patient
data will be stored in the ROMA database. The ROMA database is a secure environment that adheres
to all available international guidelines and fulfills NEN7510 and ISO 27001 regulations. Back-ups of
the entire database are made daily. Data protection and privacy regulations will be observed in
capturing, forwarding, processing and storing patient data. Patients must be informed accordingly, and
will be asked to give their consent on data-handling procedures in accordance with the Dutch Personal
Data Protection Act (in Dutch: De Wet bescherming persoonsgegevens, Wbp). The collected data will
be kept for 15 years after completion of the study. Data will be kept and stored in ROMA. Data and
official documents will also be stored at the University of Twente.
Monitoring and quality assurance
Monitoring before, during and after completion of the study will take place to ensure the rights and
safety of the patients, data integrity and validity of the study results. A DSMB is appointed before the
start of the study and the occurrence of any AEs, SAEs and/or SUSARs is reported in the electronic CRF
(see Chapter 9: Safety Reporting).
The coordinating investigator will contact and visit the participating sites whenever needed during the
course of the study. To minimize the onset of problems and to ensure the responsibilities and
procedures for data entry are well understood among the study staff, a pre-study initiation visit will be
conducted at each of the participating centres. Site monitoring visits will be done whenever needed to
sort out possible problems and to ensure data quality.
The study specific template within the EDC system ROMA2 will be pre-tested before study initiation.
During the course of the study the collected data in the electronic CRF will be checked regularly (once
per week) for missing data, entry faults, etc. If problems occur, the coordinating investigator will take
the necessary actions to reassure the quality of the data (e.g. visiting site, explanation using EDC
system, etc.). After study completion the data will be reviewed and analyses will be done as described
in Chapter 10: Data Analyses of this protocol.
Protocol adherence and amendments
Treating rheumatologists or other involved health care professionals will apply due diligence to avoid
protocol violations. The protocol will be amended and updated as needed throughout the course of
the study. A substantial amendment is defined as an amendment to the terms of the METC application,
or to the protocol or any other supporting documentation, that is likely to affect to a significant degree:




the safety or physical or mental integrity of the subjects of the trial;
the scientific value of the trial;
the conduct or management of the trial; or
the quality or safety of any intervention used in the trial.
34
Research Protocol NL52526.044.15 / ATTACG
All substantial amendments requires a written protocol amendment that must be notified to and
approved by the relevant METC, competent authority and Sobi before implementation. Nonsubstantial amendments, affecting only typing errors and administrative aspects of the study, do not
need to be notified to the accredited METC and the competent authority; but the METC must be kept
informed of such administrative changes and the sponsor should record and file these changes.
Annual progress report
The sponsor/investigator will submit a summary of the progress of the trial to the accredited METC
once a year. Information will be provided on the date of inclusion of the first subject, numbers of
subjects included and numbers of subjects that have completed the trial, serious adverse events/
serious adverse reactions, other problems, and amendments. This report will be combined with the
annual safety report.
End of study report
The sponsor will notify the accredited METC and the competent authority of the end of the study
within a period of 90 days. The end of the study is defined as when the last patient has completed the
last questionnaires at month 12. In case the study is ended prematurely, the sponsor will notify the
accredited METC and the competent authority within 15 days, including the reasons for the premature
termination. Within one year after the end of the study, the sponsor will submit a final study report
with the results of the study, including any publications/abstracts of the study, to the accredited METC
and the competent authority.
Public disclosure and publication policy
Upon study completion and finalization of the study report, the results of the study may either be
submitted for publication and/or posted in a publicly accessible database of results. Publication will
follow the International Committee of Medical Journal Editors (ICMJE) guidelines. Analysis and
publication has to comply with the conditions described in the contract with Sobi underlying this
proposal.
35
Research Protocol NL52526.044.15 / ATTACG
13.
Structured Risk Analysis
Potential risks and concerns related to this study
Summary anakinra and gout studies
Anakinra was registered for market use on March 8 2002 for treating RA. The exact mechanism of
action is known and can be found in the SPC. Pertaining to gout, anakinra has been tested in both
animals and humans. Anakinra showed inhibitory effects on the peritoneal neutrophil recruitment in
an in-vivo mouse model (BALB/C mice) of MSU crystal-induced inflammation(34). In total, 16 clinical
studies have been documented for acute gout and the usage of anakinra as treatment therapy, of
which 11 single case reports, 4 case series and one controlled open label study (22-37). No randomizedcontrolled clinical trials have been reported. The patients included in the documented studies were all
complex gouty arthritis patients with severe comorbidities and/or intolerance to conventional
therapies. Treatment with anakinra was, therefore, used as an alternative agent. Dosage regime of
anakinra differed between studies, however, the dosage 100 mg anakinra was reported in all studies.
Frequently used dosage regime was once daily 100 mg anakinra for 3 consecutive days. However, some
patients with chronic tophaceous gout used daily treatment for up to a 6 months, without any
observed adverse effects. Rapid treatment response to anakinra was observed in the majority of the
patients in the reported clinical studies. Observed side effects due to usage of anakinra were an
injection site reaction by one patient, neutropenia by another patient, one case of leukopenia, seven
infectious complications and twice a H1N1 Influenza infection occurred during anakinra treatment by
a patient, although it is not clear whether this was caused by anakinra treatment. One critically ill case
developed an infectious complication (herpes zoster) one day after completing a 6-day anakinra
treatment, although it is not clear whether this was related to the anakinra treatment. Also, one
patient developed a postoperative wound infection, although it is not clear whether the site was
already infected before anakinra treatment was initiated. Four patients could not discontinue anakinra
treatment without getting an acute flare within 4 days of stopping and one patient had a minor flare
at one month follow-up. For specific details regarding these studies, see IB.
Risks and concerns related to anakinra
The potential risks associated with anakinra for the treatment of acute gouty arthritis are:









Physical discomfort of SC treatment injection
Local (skin) injection site reaction associated with pain, inflammation, erythema, or
ecchymoses
Serious infections including respiratory infections and skin infections, Influenza infections
Allergic reaction and anaphylaxis (angioedema, urticarial and pruritus) to anakinra or other
constituents, including latex
Decreased neutrophil count, potentially leading to neutropenia
Drug interaction between ULT and anakinra
Elevated levels of liver enzymes
Gastrointestinal disturbances related to liver disorders (yellow skin and eyes, nausea, loss of
appetite, dark-colored urine, light-colored stools)
Headaches
36
Research Protocol NL52526.044.15 / ATTACG
These risks are defined according to the documented information and side effects in the literature and
the concerns as listed in the SPC. For elaborate explanations regarding these side effects see SPC and
IB.
Other risks and concerns
NSAIDs and colchicine are intended as prophylactics for gout flares when initiating ULT. Patients
receiving anakinra treatment or prednisolone treatment (when allocated into the SoC group) will not
receive colchicine or NSAID prophylactics when initiating ULT. Relapse of a gout flare might occur
sooner in this population compared to the other study arm that will receive prophylactics.
Reducing and managing the potential risks and concerns
To ensure the risks associated with the injection of anakinra remain limited, the inclusion and exclusion
criteria of this study are strict. Eligible patients will be excluded from the study if there are
contraindications to the use of anakinra or any of its constituents. This will reduce the chance of allergic
reactions to anakinra in the study population. Additionally, patients with pre-existing neutropenia or
with untreated infections will not be included in the study. Also, pregnant, lactating women and
women who are planning on becoming pregnant within the study period (12 months) are not allowed
to participate in the study, as the effect of anakinra on unborn or nursed children is unknown. Patients
using TNF inhibitors are also excluded from this study, as concurrent use of anakinra with TNF
inhibitors has been shown to be associated with the development of severe infections and
neutropenia.
A DSMB will be established to ensure the safety of the participants. As no information is available on
the possible drug reaction between ULT and anakinra, any reported SAE or SUSAR will be evaluated
for possible interaction by the DSMB as well as the treating rheumatologist. Moreover, patients
experiencing any side effects or other AE will be instructed to immediately contact their treating
rheumatologist. The treating rheumatologist will give the patient the needed care and report any SAE
and/or SUSARs to the sponsor. The sponsor will report the events in accordance with Chapter 9: Safety
Reporting, of this protocol. If needed, the sponsor and/or DSMB will decide to prematurely terminate
the study if there is a possibility that the safety of the participants is being put in jeopardy.
Anakinra has been used for treating patients with RA since 2002. The long experience with this product
in RA patients has resulted in a good description of its safety profile and the possible side effects. Such
information has contributed to clearly defining the potential risks associated with using anakinra in the
present study. In addition, patients with chronic RA may use anakinra daily for long periods of time
(years if needed) to treat the disease. Therefore, it is expected that the risks associated with the 5 day
anakinra treatment in this study will be limited and is therefore judged an acceptable treatment
duration. Moreover, the applied daily dosage of 100mg anakinra in this study is the same as the
recommended dosage for treating RA patients and as used in other documented studies, suggesting
the dosage is acceptable.
When a new acute gout flare arises after the first study week (baseline – day 7), all patients should
contact their treating rheumatologist who will treat the patient with the best available care. The group
not receiving prophylactic agents will receive the same optimal care as patients receiving
prophylactics. In some cases it might be needed to break the randomization (treatment) code to be
37
Research Protocol NL52526.044.15 / ATTACG
able to provide the patient the best care. Patients will be instructed by the research nurse and/or their
treating rheumatologist on how to handle in case another flare arises. By applying the above, the
concerns associated with not taking prophylactics will remain limited.
The risks associated with this study have been evaluated and minimized by setting up strict inclusion
and exclusion criteria and by establishing a DSMB. Not all risks could however be eliminated. The
remaining risks are acceptable since the risks are not considered to be severe or life threatening.
38
Research Protocol NL52526.044.15 / ATTACG
14.
Reference List
1.
Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48 Suppl
2:ii2-ii8.
2.
Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK
and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann
Rheum Dis. 2008;67(7):960-6.
3.
Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318-28.
4.
Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223.
5.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population:
the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum.
2011;63(10):3136-41.
6.
B L, T W, Hn Z, Ww Y, Hp Y, Cx L, et al. The prevalence of hyperuricemia in China: a metaanalysis. BMC Public Health. 2011;11(832):1471-2458.
7.
Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and
hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol.
2004;31(8):1582-7.
8.
Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z, et al. Dietary and lifestyle changes associated
with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern
China. J Rheumatol. 2008;35(9):1859-64.
9.
Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res
Ther. 2006;8(1):12.
10.
Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of
Contraindications and Prescription of Pharmacologic Therapies for Gout. The American Journal
of Medicine. 2011;124(2):155-63.
11.
Tausche AK, Jansen TL, Schroder HE, Bornstein SR, Aringer M, Muller-Ladner U. Gout--current
diagnosis and treatment. Dtsch Arztebl Int. 2009;106(34-35):549-55.
12.
Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res
Ther. 2009;11(4):23.
13.
Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to
know. Ther Adv Chronic Dis. 2012;3(6):271-86.
14.
Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis
of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol.
2004;31(12):2429-32.
15.
Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of
Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory
prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-61.
39
Research Protocol NL52526.044.15 / ATTACG
16.
Richtlijn Jicht. Utrecht (NL): Nederlandse Vereniging voor Reumatologie, 2013.
17.
Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the
initiation of urate-lowering therapy: analysis of data from three phase III trials. Clinical
therapeutics. 2010;32(14):2386-97.
18.
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based
recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing
Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis.
2006;65(10):1312-24.
19.
Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for
therapy. Arthritis Rheum. 2007;56(10):3183-8.
20.
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate
the NALP3 inflammasome. Nature. 2006;440(7081):237-41.
21.
Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like
receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium
urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005;52(9):2936-46.
22.
Bartov JB, Ali Y. Successful use of the interleukin 1 antagonist, anakinra, in a patient with gout,
chronic kidney disease, and aplastic anemia. J Clin Rheumatol. 2013;19(8):454-6.
23.
Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra's efficacy is variable in refractory
gout: report of ten cases. Semin Arthritis Rheum. 2010;40(3):210-4.
24.
Direz G, Noel N, Guyot C, Toupance O, Salmon JH, Eschard JP. Efficacy but side effects of
anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal
chronic renal failure. Joint Bone Spine. 2012;79(6):631.
25.
Donmez S, Pamuk ON. Chronic tophaceous gout. J Rheumatol. 2014;41(3):554-5.
26.
Funck-Brentano T, Salliot C, Leboime A, Zafrani L, Servais A, Larousserie F, et al. First
observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine.
Rheumatology (Oxford). 2011;50(3):622-4.
27.
Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in
complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013;65(8):1381-4.
28.
Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout
inflammation. Arthritis Rheum. 2009;61(9):1268-70.
29.
McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management
of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann
Rheum Dis. 2007;66(12):1683-4.
30.
Nocturne G, Ora J, Ea HK, Liote F. Influenza A H1N1 and anakinra exposure in a patient with
gout. Joint Bone Spine. 2010;77(4):369-70.
40
Research Protocol NL52526.044.15 / ATTACG
31.
O'Brien KL, Pereira SE, Wagner J, Shadman M, Hendrie P, Nelson K, et al. Transfusionassociated graft-versus-host disease in a liver transplant recipient: an unusual presentation
and review of the literature. Transfusion. 2013;53(1):174-80.
32.
Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty
arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123.
33.
Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin
Rheumatol. 2009;15(7):366.
34.
So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout.
Arthritis Res Ther. 2007;9(2):R28.
35.
Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.
Int J Rheum Dis. 2011;14(3):e33-7.
36.
Vitale A, Cantarini L, Rigante D, Bardelli M, Galeazzi M. Anakinra treatment in patients with
gout and type 2 diabetes. Clin Rheumatol. 2014.
37.
Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically
ill patients. Seminars in Arthritis and Rheumatism 2015;[In Press, Corrected Proof].
38.
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis
Rheum. 1980;23(2):137-45.
39.
Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual
framework and item selection. Medical care. 1992;30(6):473-83.
40.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and
activity impairment instrument. PharmacoEconomics. 1993;4(5):353-65.
41.
Committee for medicinal products for human use. Guideline on the choice of the noninferiority margin. London: European Medicines Agency (EMEA); 2005.
42.
Guidance for Industry: Non-Inferiority Clinical Trials In: Services USDoHaH, editor. Rockville,
Maryland, USA: Food and Drug Administration; 2010.
43.
Piaggio G, Elbourne DR, Pocock SJ, Evans SW, Altman DG, f CG. Reporting of noninferiority and
equivalence randomized trials: Extension of the CONSORT 2010 statement. JAMA.
2012;308(24):2594-604.
44.
Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, et al. Lumiracoxib 400 mg once
daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares
of gout. Rheumatology. 2007;46(7):1126-32.
45.
Schumacher Jr HR, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised
double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. Bmj.
2002;324(7352):1488-92.
46.
Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, Pryhuber KG, et al. Efficacy and safety
profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg
41
Research Protocol NL52526.044.15 / ATTACG
three times daily in acute gout: A randomized controlled trial. Arthritis & Rheumatism.
2004;50(2):598-606.
47.
Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, et al. Rilonacept in the
treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin
as the active comparator. Arthritis Res Ther. 2013;15(1):R25.
48.
Matilde Sanchez M, Chen X. Choosing the analysis population in non-inferiority studies: per
protocol or intent-to-treat. Statistics in medicine. 2006;25(7):1169-81.
49.
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for
missing data in epidemiological and clinical research: potential and pitfalls. Bmj.
2009;338:b2393.
50.
World medical association declaration of helsinki: Ethical principles for medical research
involving human subjects. JAMA. 2013;310(20):2191-4.
42
Research Protocol NL52526.044.15 / ATTACG
15.
Appendices
I.
CRF Information
II.
Patient flare diary
III.
PROs questionnaires
IV.
DSMB Charter
43
ATTACG studie
CRF - TOELATINGSCRITERIA (Pagina 1/2)
Datum
(dd mm jjjj)
Patiëntcode/
medicatiecode:
-
-
Centrum (kies 1):
MST
VieCuri MC
ZGT
MCL
Rijnstate
Ropcke-Zweers Ziekenhuis
Initialen
behandelaar
Locatie centrum:
INCLUSIECRITERIA
1. Poliklinische patiënt met microscopisch kristalbewezen
gedocumenteerde jicht
Ja
Nee
2. Op moment van inclusie is de patiënt 18 jaar of ouder
Ja
Nee
3. Patiënt heeft de patiënteninformatie ondertekend
Ja
Nee
Ja
Nee
Ja
Nee
Ja
Nee
EXCLUSIECRITERIA
1. Patiënt heeft een absolute contra-indicatie voor alle beschikbare
urinezuur verlagende therapie (allopurinol, febuxostat, benzbromaron)
Contra-indicaties allopurinol: Overgevoeligheid voor de werkzame stof (allopurinol)
of voor één van de hulpstoffen (zie hiervoor de officiële productinformatie)
Contra-indicaties febuxostat: Overgevoeligheid voor de werkzame stof (febuxostat)
of voor één van de hulpstoffen (zie hiervoor de officiële productinformatie).
Contra-indicaties benzbromaron: Overgevoeligheid voor het werkzaam bestanddeel
(benzbromaron) of voor één van de hulpstoffen (zie hiervoor de officiële productinformatie).
Patiënten met bekende leverziekte. Gelijktijdig gebruik van hepatotoxische geneesmiddelen,
in het bijzonder anti-tuberculose agentia. Hepatische porfyrie. Ernstige nierinsufficiëntie
(klaring < 30 ml/min). Patiënten met hyperuraturie hoger dan 700 mg/24 uur (= 4,2 mmol/24
uur). Urolithiasis. Acute jichtaanval.
2. Patiënt heeft een absolute contra-indicatie voor anakinra
Contra-indicaties anakinra: Overgevoeligheid voor de werkzame stof (anakinra) of voor
één van de hulpstoffen (citroenzuur watervrij, natriumchloride, dinatriumedetaat-dihydraat,
polysorbaat 80, natriumhydroxide, water voor injectie), of voor eiwitten geproduceerd met
behulp van E. coli. Anakinra (Kineret) mag niet worden gebruikt bij patiënten met ernstige
nierfunctiestoornissen (CLcr < 30 ml/minuut). Er mag geen Kineret-behandeling worden
begonnen bij patiënten met neutropenie (Absolute Neutrophil Count <1,5 x 109/l).
3. Aanwezigheid van leveraandoeningen die volgens de
behandelende arts deelname aan de studie onmogelijk maken
Versie 3 - 09/02/2016
ATTACG studie
CRF - TOELATINGSCRITERIA (Pagina 2/2)
4. Patiënt heeft een absolute contra-indicatie voor alle 3
standaard jichtaanvalmiddelen; colchicine, naproxen en prednisolon
Ja
Nee
Contra-indicaties colchicine: Overgevoeligheid voor de werkzame stof (colchicine) of voor één van de
hulpstoffen (microkrystallijne cellulose (E460), magnesiumstearaat (E470b), lactose, natriumcarboxyzetmeel).
Vrouwen in de vruchtbare leeftijd, tenzij doeltreffende anticonceptie-maatregelen worden genomen. Patiënten
met ernstige nierfunctiestoornissen. Patiënten met ernstige leverfunctiestoornissen.
Contra-indicaties naproxen: Overgevoeligheid voor naproxen of voor één van de hulpstoffen
(aardappelzetmeel, lactose, hydroxypropylcellulose (200 CP), magnesiumstearaat, watervrij colloïdaal
siliciumdioxide). Naproxen mag ook niet toegediend worden aan patiënten, die na toediening van
acetylsalicylzuur of andere prostaglandinesynthetaseremmende middelen een allergische reactie vertoond
hebben, zoals astma, rhinitis of urticaria. Ernstige anafylactoïde reacties zijn bij deze patiënten gerapporteerd.
Naproxen mag in principe niet toegediend worden aan patiënten met ulceraties van het maagdarmkanaal,
gastritis congestiva of gastritis atrophica, maagdarmbloedingen of andere bloedingen zoals cerebrovasculaire
bloedingen. Ernstige nierinsufficiëntie
Contra-indicaties prednisolon: Overgevoeligheid voor prednisolon of één van de andere bestanddelen
van de tabletten (lactose, magnesiumstearaat (E470b), siliciumdioxide (E551), aardappelzetmeel,
voorverstijfseld aardappelzetmeel, natrium (aardappel)zetmeelglycollaat. Ulcus ventriculi en ulcus duodeni.
Acute infectieuze processen, met name virusinfecties en systemische schimmelinfecties.
Tropische worminfecties. Toediening na vaccinatie met levend verzwakt virus. Herpes simplex oculi.
5. De patiënt heeft een verleden van latex sensitiviteit of allergie
Ja
Nee
6. Actueel gebruik van urinezuur verlagende therapie (UVT)
Ja
Nee
7. Patiënt gebruikt andere interleukine-1 therapieën
Ja
Nee
Ja
Nee
Ja
Nee
10. Patiënt is een vrouw die binnen de studie periode zwanger denkt
te raken (12 maanden)
Ja
Nee
11. Patiënt heeft een actieve of terugkerende bacteriële, schimmel
of virale infectie
Ja
Nee
12. Patiënt gebruikt TNF-remmers
Ja
Nee
Ja
Nee
Ja
Nee
Tot UVT behoren allopurinol, febuxostat en benzbromaron.
Tot andere interleukine-1 therapieën behoren canakinumab en rilonacept.
8. Patiënt rapporteert geen tot milde jicht gerelateerde pijn
9. Patiënt is zwanger of geeft borstvoeding
Tot TNF-remmers behoren: Certolizumab, Golimumab, adalimumab, etanercept, infliximab
13. Patiënt beschikt over onvoldoende beheersing van de
Nederlandse taal om zelfstandig vragenlijsten in te vullen
Is de patiënt toelaatbaar tot de studie volgens de bovengenoemde
criteria?
(Een patiënt is alleen toelaatbaar als aan alle inclusie criteria voldaan is en niet aan het
exclusiecriteria)
Versie 3 - 09/02/2016
ATTACG studie
CRF - PATIËNTKARAKTERISTIEKEN
Eerstelijnszorg (via de huisarts, spoedeisende hulp)
Patiënt is binnengekomen via:
Tweedelijnszorg (via de polikliniek reumatologie)
Biometrische kenmerken
1. Geslacht
Man
Vrouw
2. Leeftijd (jaren)
Geschat?
3. Lengte (cm)
Ja
Nee
4. Gewicht (kg)
Ja
Nee
5. Diastolische bloeddruk (mm/Hg)
6. Systolische bloeddruk (mm/Hg)
7. Hartslag (per minuut)
Versie 3 - 09/02/2016
ATTACG studie
CRF - JICHT STATUS
Jicht status (1/4)
Diagnosedatum
1. Jicht diagnose datum
-
(dd-mm-jjjj)
-
Dit is de datum waarop voor het eerst jicht werd gediagnosticeerd bij de patiënt. Dit kan zijn door de
huisarts, reumatoloog of iemand anders.
2. Jicht type
Monoarticulair
Oligoarticulair
Polyarticulair
Bij monoarticulaire jicht is 1 gewricht aangedaan door jicht. Bij Oligoarticulaire jicht zijn er meer dan 1,
maar minder dan 5 gewrichten aangedaan. Bij polyarticulaire jicht zijn er meer dan 5 gewrichten
aangedaan.
3. Topheuze jicht
Ja
Nee
4. Beloop
Intermitterend
Chronisch
5. Aantal jichtaanvallen.
(Noteer het aantal jichtaanvallen sinds
het vorige bezoek. Noteer bij het
eerste bezoek het aantal aanvallen
over de afgelopen 12 maanden)
Versie 3 - 09/02/2016
ATTACG studie
CRF - JICHT STATUS
Jicht status (2/4)
6. Voldoet de patiënt aan het volgende: Ten minste 1 episode van zwelling, pijn of
gevoeligheid in een perifeer gewricht of bursa (nu en/of ooit in het verleden)
Ja (ga door naar vraag 7)
Nee (je hoeft verder niets in te vullen voor jicht status, ga door naar sectie comborbiditeiten)
7. Voldoet de patiënt aan het volgende: Aanwezigheid van urinezuurkristallen in een
symptomatisch gewricht of bursa (i.e. in gewrichtsvloeistof) of tophus
Ja (je hoeft verder niets in te vullen voor jicht status, ga door naar sectie comborbiditeiten)
Nee (ga door naar vraag 8)
8. Patroon van gewricht/bursa betrokkenheid tijdens symptomatische episode(n) nu en/of
ooit in het verleden (1 antwoord mogelijk):
Symptomatische episoden zijn periodes van symptomen inclusief alle soorten zwelling, pijn, gevoeligheid in
een perifeer gewricht of bursa.
Gewricht(en) of bursa(e) anders dan de enkel, middenvoet of MTP1 (of de betrokkenheid
van deze alleen als onderdeel van een polyarticulair voorval)
Enkel OF middenvoet (als onderdeel van een monoarticulaire of oligoarticulaire episode
zonder de betrokkenheid van MTP1)
MTP1 (als onderdeel van een monoarticulaire of oligoarticulaire episode)
9. Kenmerken van symptomatische episode(n) (nu en/of ooit in het verleden) (1 antwoord
mogelijk):
i.
Erytheem rondom het aangetaste gewricht (patiënt-gerapporteerd of door de arts
waargenomen)
ii. Aanraking of druk uitoefenen op het aangetaste gewricht wordt niet verdragen
iii. Grote moeite met lopen of het onvermogen om aangetaste gewricht te gebruiken
Geen kenmerken
1 kenmerk
2 kenmerken
3 kenmerken
Versie 3 - 09/02/2016
ATTACG studie
CRF - JICHT STATUS
Jicht status (3/4)
10. Tijdsverloop van episode(n) nu en/of ooit in het verleden:
Bij aanwezigheid (ooit) van 2 of meer is er sprake van een typische episode, ongeacht anti-inflammatoire
behandeling:
i. Tijd tot maximaal bereikte pijn <24 uur
ii. Resolutie van symptomen is minder of gelijk dan 14 dagen
iii. Volledige resolutie (tot baseline niveau) tussen symptomatische episoden
Geen typerende episode(n)
1 Typische episode
Terugkerende typerende episode(n)
11. Klinisch bewijs van tophi:
Druipende of krijt - achtige subcutane knobbel onder transparante huid, vaak met bovenliggende vasculariteit,
gelegen in typische locaties: gewrichten, oren, bursitis olecrani, vingertoppen, pezen (bijv. Achilles).
Afwezig
Aanwezig
12. Urinezuurspiegel:
Gemeten middels de uricase methode. Idealiter gemeten op een tijdstip wanneer er door de patiënt geen
urinezuurverlagende therapie werd ingenomen en 4 weken na de start van de episode bij de patiënt (i.e.,
tijdens interkritische periode); als praktisch uitvoerbaar, opnieuw testen onder dergelijke condities. De
hoogste waarde, onafhankelijk van wanneer gemeten, dient te worden gescoord.
<4 mg/dL (<0.24 mmol/L)
4 - <6 mg/dL (0.24 - <0.36 mmol/L)
6 - <8 mg/dL (0.36 - <0.48 mmol/L)
8 - <10 mg/dL (0.48 - <0.60 mmol/L)
groter of gelijk aan 10 mg/dL (groter of gelijk aan 0.6 mmol/L)
13. Analyse gewrichtsvloeistof van een symptomatisch (nu en/of ooit in het verleden)
gewricht of bursa:
Dient beoordeeld te worden door een getrainde waarnemer.
Niet gedaan
Urinezuurkristallen negatief
Versie 3 - 09/02/2016
ATTACG studie
CRF - JICHT STATUS
Jicht status (4/4)
14. Beeldvormend onderzoek van uraatafzetting in symptomatisch (nu en/of ooit in het
verleden) gewricht of bursa:
Echografisch bewijs van dubbel contour sign (zie uitleg *) of DECT vertoont uraatafzetting (zie uitleg **).
Niet gedaan
Afwezig
Aanwezig (geldt voor beide technieken)
* Hyperechoische onregelmatige versterkingen die onafhankelijk zijn van de insonatie hoek van de
ultrasoon geluid bundel (noot: valspositief "dubbel contour sign"(artefact) zou kunnen verschijnen aan het
hyaline kraakbeen oppervlak maar dienen te verdwijnen met een verandering van de insonatie hoek van de
sonde).
** Aanwezigheid van kleurgecodeerd uraat bij de articulaire of peri-articulaire plaatsen. Afbeeldingen zijn
verkregen door het gebruik van een dual energy computer tomografie (DECT) scanner, met data verworven
bij 80 en 140kV en geanalyseerd met jicht-specifieke software met een twee materiaal decompositie
algoritme dat uraat kleur codeerd. Een positieve scan is gedefinieerd als de aanwezigheid van
kleurgecodeerd uraat by articulaire of peri-articulaire plaatsen. Nagelbed, submillimeter, huid, 'motion',
'beam hardening' en vasculaire artefacten dienen niet te worden geïnterpreteerd als bewijs voor DECT
uraatafzetting.
15. Beeldvormend onderzoek van jicht-gerelateerde gewrichtsschade:
Conventionele radiografie van de handen en/of voeten toont ten minste één erosie (zie uitleg ***)
Niet gedaan
Afwezig
Aanwezig
*** Erosie wordt gedefinieerd als een corticale breuk met een sclerotische marge en overhangende rand;
exclusief DIP gewrichten en zeemeeuw uiterlijk.
Versie 3 - 09/02/2016
ATTACG studie
CRF - COMORBIDITEITEN
COMORBIDITEITEN
Cardiovasculaire ziekte
Ja
Nee
Hyperlipidemie
Ja
Nee
Hypertensie
Ja
Nee
Lymfoproliferatieve maligniteit
Ja
Nee
Metabolisch syndroom
syndroom
Nierinsufficientie
Ja
Nee
Ja
Nee
Obesitas
Ja
Nee
Overige malignitieit
Ja
Nee
Overige comorbiditeiten
Ja
Nee
Indien ja, welke comorbiditeiten?
Versie 3 - 09/02/2016
ATTACG studie
CRF - LABORATORIUM
Serum urine zuur (mmol/l)
CRP (mg/l)
Versie 3 - 09/02/2016
,
,
ATTACG studie
CRF - JICHTMEDICATIE
Jichtmedicatie Noteer hier ALLE medicatie die voor JICHT gestart is op moment van inclusie of gestart is
tijdens de studie op recept van de reumatoloog, zowel ontstekingsremmende als urinezuur verlagende
therapieën. Voor codes zie onderaan de pagina. Laat het veld stopdatum leeg indien de medicatie
voortgezet wordt.
Naam
Dosering
Eenheden
Frequentie
,
per
Startdatum
-
Route
Stopdatum
-
-
-
Reden van stoppen
Niet effectief
Hersteld
Last van Bijwerkingen
Indien last van Bijwerkingen, wat waren de bijwerkingen?
Naam
Dosering
Eenheden
Route
per
,
Startdatum
-
Frequentie
Stopdatum
-
-
Reden van stoppen
Hersteld
Niet effectief
Last van Bijwerkingen
Indien last van Bijwerkingen, wat waren de bijwerkingen?
Codes route
1. Intra-articluair
2. Intramusculair
3. Intraveneus
4. Intranasaal
Versie 3 - 09/02/2016
5. Oraal
6. Rectaal
7. Subcutaan
8. Overig
-
ATTACG studie
CRF - OVERIGE MEDICATIE
Overige medicatie (Noteer hier alle medicatie die op dit moment voor aandoeningen anders dan jicht
gebruikt worden of die in de afgelopen 12 maanden zijn gebruikt)
Naam
Dosering
Eenheden
,
Frequentie
Route
per
Startdatum
Stopdatum (indien van toepassing)
-
-
-
-
Reden van stoppen:
Hersteld
Niet effectief
Last van bijwerkingen
Indien last van bijwerkingen, wat waren de bijwerkingen?
Naam
Dosering
Eenheden
Route
per
,
Startdatum
-
Frequentie
Stopdatum
-
-
Reden van stoppen:
Hersteld
Niet effectief
-
Last van bijwerkingen
Indien last van bijwerkingen, wat waren de bijwerkingen?
Codes route
1. Intra-articluair
2. Intramusculair
3. Intraveneus
4. Intranasaal
5. Oraal
6. Rectaal
7. Subcutaan
8. Overig
59360
Versie 3 - 09/02/2016
ATTACG studie
CRF - BIJWERKINGEN
Infectieziekte
Ja
Nee
Leveraandoeningen na starten medicatie
Ja
Nee
Ja
Nee
Ja
Nee
Verslechtering nierfunctie
Ja
Nee
Tumor lysis
Ja
Nee
Zwanger
Ja
Nee
Overig
Ja
Nee
Hart en vaataandoeningen
Verslechtering van serum urinezuur
Indien ja, welke?
Versie 3 - 09/02/2016
ATTACG studie
CRF - ADVERSE EVENTS
1. Omschrijving van de bijwerking
2. Begindatum bijwerking (dd-mm-jjjj)
-
3. Stopdatum bijwerking (dd-mm-jjjj)
-
-
-
4. Hoe is het met deze bijwerking afgelopen bij de patiënt?
Hersteld
Hersteld met restverschijnselen
Herstellende
Overleden
Onbekend
5. Is deze bijwerking behandeld?
Nee
Onbekend
Ja
6. Relatie tot studie medicatie?
Verdacht
Samengaand
Interactie
Geen / n.v.t.
Anders
7. Zijn er naast de studie medicatie mogelijk andere oorzaken of omstandigheden die de
bijwerking kunnen hebben veroorzaakt of verergerd?
Nee
Onbekend
Ja
8. Heeft de bijwerking geleid tot een van de volgende situaties?
Overlijden
Levensbedreigende situatie
Ziekenhuisopname
Blijvende arbeidsongeschiktheid
Aangeboren afwijking
Overige ernstige afwijkingen
9. Welke actie is er ondernomen?
Geen
Dosering verhoogd
Bijvend gestaakt
Dosering onveranderd
Tijdelijk gestaakt
Onbekend
Dosering verlaagd
Anders / n.v.t.
Versie 3 - 09/02/2016
ATTACG studie
CRF - STUDIE UITVAL
1. Datum laatste dosis studie medicatie
-
-
2. Datum studie uitval
-
-
3. Belangrijkste reden voor uitval
(Serious) Adverse events
SUSAR
Besluit van patiënt
Besluit behandelaar
Patiënt overleden
Overige reden, namelijk:
4. Specificeer de reden voor uitval hieronder nader
Versie 3 - 09/02/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 1 (Pagina 1 van 3)
Patiëntcode./
medicatiecode
1. Wat is de datum waarop deze jichtaanval begon? (dd-mm-jjjj)
-
-
2. Wat is de datum vandaag? (dd-mm-jjjj)
-
-
3. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
1
geen pijn
2
milde pijn
3
4
5
matige pijn
veel pijn
extreme pijn
4. Hoe gevoelig voor aanraking zijn de delen van uw lichaam die door jicht zijn
aangedaan vandaag? (1 vakje volledig inkleuren)
1
2
3
4
5
niet
gevoelig
licht
gevoelig
redelijk
gevoelig
heel
gevoelig
extreem
gevoelig
5. Hoe gezwollen zijn de delen van uw lichaam die door jicht zijn aangedaan vandaag?
(1 vakje volledig inkleuren)
1
niet
gezwollen
2
enigszins
gezwollen
3
4
5
redelijk
gezwollen
heel
gezwollen
extreem
gezwollen
6. Wat vindt u van het beloop van uw klachten sinds het begin van deze jichtaanval? (1
vakje volledig inkleuren)
1
2
geheel
zeer veel
verdwenen verbeterd
3
4
veel
verbeterd
enigszins
verbeterd
5
6
7
8
9
niet
iets
veel
zeer veel
niet van
veranderd verslechterd verslechterd verslechterd toepassing
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 1 (Pagina 2 van 3)
7. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
Helemaal
geen pijn
0
1
2
3
4
5
6
7
8
9
10
Ondraaglijke
pijn
8. Als u denkt aan alle manieren waarop uw jicht u vandaag beïnvloedt, hoe gaat het
dan met u? (1 vakje volledig inkleuren)
Zeer slecht
Zeer goed
0
1
2
3
4
5
6
7
8
9
10
9. Heeft u last van bijwerkingen? Zo ja, noteer hieronder de bijwerkingen die u vandaag
ervaart: (1 letter per vakje)
10. Heeft u vandaag uw studiemedicatie ingenomen? (1 vakje volledig inkleuren)
Nee
Ja, alle medicijnen zoals voorgeschreven
Ja, maar gedeeltelijk/niet alles zoals voorgeschreven
11. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? Wilt u dit aangeven door een
verticaal streepje ( I ) te zetten op onderstaande lijn?
helemaal
geen pijn
ondraaglijke
pijn
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 1 (Pagina 3 van 3)
12. Heeft u de afgelopen 24 uur naast uw onderzoeksmedicatie, nog andere medicijnen
ingenomen om uw jichtaanval te bestrijden? Zo ja, noteer hieronder de medicatie die u
heeft ingenomen. Hieronder valt ook paracetamol en ibuprofen gebruik: (1 letter per
vakje).
Medicijn 1
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 2
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 3
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 2 (Pagina 1 van 3)
Patiëntcode./
medicatiecode
1. Wat is de datum vandaag? (dd-mm-jjjj)
-
-
2. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
1
2
3
4
5
geen pijn
milde pijn
matige pijn
veel pijn
extreme pijn
3. Hoe gevoelig voor aanraking zijn de delen van uw lichaam die door jicht zijn
aangedaan vandaag? (1 vakje volledig inkleuren)
1
2
3
4
5
niet
gevoelig
licht
gevoelig
redelijk
gevoelig
heel
gevoelig
extreem
gevoelig
4. Hoe gezwollen zijn de delen van uw lichaam die door jicht zijn aangedaan vandaag?
(1 vakje volledig inkleuren)
1
2
3
4
5
niet
gezwollen
enigszins
gezwollen
redelijk
gezwollen
heel
gezwollen
extreem
gezwollen
5. Wat vindt u van het beloop van uw klachten sinds het begin van deze jichtaanval? (1
vakje volledig inkleuren)
1
2
geheel
zeer veel
verdwenen verbeterd
3
4
veel
verbeterd
enigszins
verbeterd
5
6
7
8
9
niet
iets
veel
zeer veel
niet van
veranderd verslechterd verslechterd verslechterd toepassing
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 2 (Pagina 2 van 3)
6. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
Helemaal
geen pijn
0
1
2
3
4
5
6
7
8
9
10
Ondraaglijke
pijn
7. Als u denkt aan alle manieren waarop uw jicht u vandaag beïnvloedt, hoe gaat het
dan met u? (1 vakje volledig inkleuren)
Zeer slecht
Zeer goed
0
1
2
3
4
5
6
7
8
9
10
8. Heeft u last van bijwerkingen? Zo ja, noteer hieronder de bijwerkingen die u vandaag
ervaart: (1 letter per vakje)
9. Heeft u vandaag uw studiemedicatie ingenomen? (1 vakje volledig inkleuren)
Nee
Ja, alle medicijnen zoals voorgeschreven
Ja, maar gedeeltelijk/niet alles zoals voorgeschreven
10. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? Wilt u dit aangeven door een
verticaal streepje ( I ) te zetten op onderstaande lijn?
helemaal
geen pijn
ondraaglijke
pijn
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 2 (Pagina 3 van 3)
11. Heeft u de afgelopen 24 uur naast uw onderzoeksmedicatie, nog andere medicijnen
ingenomen om uw jichtaanval te bestrijden? Zo ja, noteer hieronder de medicatie die u
heeft ingenomen. Hieronder valt ook paracetamol en ibuprofen gebruik: (1 letter per
vakje).
Medicijn 1
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 2
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 3
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 3 (Pagina 1 van 3)
Patiëntcode./
medicatiecode
1. Wat is de datum vandaag? (dd-mm-jjjj)
-
-
2. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
1
geen pijn
2
milde pijn
3
4
5
matige pijn
veel pijn
extreme pijn
3. Hoe gevoelig voor aanraking zijn de delen van uw lichaam die door jicht zijn
aangedaan vandaag? (1 vakje volledig inkleuren)
1
2
3
4
5
niet
gevoelig
licht
gevoelig
redelijk
gevoelig
heel
gevoelig
extreem
gevoelig
4. Hoe gezwollen zijn de delen van uw lichaam die door jicht zijn aangedaan vandaag?
(1 vakje volledig inkleuren)
1
2
3
4
5
niet
gezwollen
enigszins
gezwollen
redelijk
gezwollen
heel
gezwollen
extreem
gezwollen
5. Wat vindt u van het beloop van uw klachten sinds het begin van deze jichtaanval? (1
vakje volledig inkleuren)
1
2
geheel
zeer veel
verdwenen verbeterd
3
4
veel
verbeterd
enigszins
verbeterd
5
6
7
8
9
niet
iets
veel
zeer veel
niet van
veranderd verslechterd verslechterd verslechterd toepassing
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 3 (Pagina 2 van 3)
6. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
Helemaal
geen pijn
0
1
2
3
4
5
6
7
8
9
10
Ondraaglijke
pijn
7. Als u denkt aan alle manieren waarop uw jicht u vandaag beïnvloedt, hoe gaat het
dan met u? (1 vakje volledig inkleuren)
Zeer slecht
Zeer goed
0
1
2
3
4
5
6
7
8
9
10
8. Heeft u last van bijwerkingen? Zo ja, noteer hieronder de bijwerkingen die u vandaag
ervaart: (1 letter per vakje)
9. Heeft u vandaag uw studiemedicatie ingenomen? (1 vakje volledig inkleuren)
Nee
Ja, alle medicijnen zoals voorgeschreven
Ja, maar gedeeltelijk/niet alles zoals voorgeschreven
10. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? Wilt u dit aangeven door een
verticaal streepje ( I ) te zetten op onderstaande lijn?
helemaal
geen pijn
ondraaglijke
pijn
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 3 (Pagina 3 van 3)
11. Heeft u de afgelopen 24 uur naast uw onderzoeksmedicatie, nog andere medicijnen
ingenomen om uw jichtaanval te bestrijden? Zo ja, noteer hieronder de medicatie die u
heeft ingenomen. Hieronder valt ook paracetamol en ibuprofen gebruik: (1 letter per
vakje).
Medicijn 1
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 2
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 3
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 4 (Pagina 1 van 3)
Patiëntcode./
medicatiecode
1. Wat is de datum vandaag? (dd-mm-jjjj)
-
-
2. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
1
2
3
4
5
geen pijn
milde pijn
matige pijn
veel pijn
extreme pijn
3. Hoe gevoelig voor aanraking zijn de delen van uw lichaam die door jicht zijn
aangedaan vandaag? (1 vakje volledig inkleuren)
1
2
3
4
5
niet
gevoelig
licht
gevoelig
redelijk
gevoelig
heel
gevoelig
extreem
gevoelig
4. Hoe gezwollen zijn de delen van uw lichaam die door jicht zijn aangedaan vandaag?
(1 vakje volledig inkleuren)
1
2
3
4
5
niet
gezwollen
enigszins
gezwollen
redelijk
gezwollen
heel
gezwollen
extreem
gezwollen
5. Wat vindt u van het beloop van uw klachten sinds het begin van deze jichtaanval? (1
vakje volledig inkleuren)
1
2
geheel
zeer veel
verdwenen verbeterd
3
4
veel
verbeterd
enigszins
verbeterd
5
6
7
8
9
niet
iets
veel
zeer veel
niet van
veranderd verslechterd verslechterd verslechterd toepassing
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 4 (Pagina 2 van 3)
6. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
Helemaal
geen pijn
0
1
2
3
4
5
6
7
8
9
10
Ondraaglijke
pijn
7. Als u denkt aan alle manieren waarop uw jicht u vandaag beïnvloedt, hoe gaat het
dan met u? (1 vakje volledig inkleuren)
Zeer slecht
Zeer goed
0
1
2
3
4
5
6
7
8
9
10
8. Heeft u last van bijwerkingen? Zo ja, noteer hieronder de bijwerkingen die u vandaag
ervaart: (1 letter per vakje)
9. Heeft u vandaag uw studiemedicatie ingenomen? (1 vakje volledig inkleuren)
Nee
Ja, alle medicijnen zoals voorgeschreven
Ja, maar gedeeltelijk/niet alles zoals voorgeschreven
10. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? Wilt u dit aangeven door een
verticaal streepje ( I ) te zetten op onderstaande lijn?
helemaal
geen pijn
ondraaglijke
pijn
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 4 (Pagina 3 van 3)
11. Heeft u de afgelopen 24 uur naast uw onderzoeksmedicatie, nog andere medicijnen
ingenomen om uw jichtaanval te bestrijden? Zo ja, noteer hieronder de medicatie die u
heeft ingenomen. Hieronder valt ook paracetamol en ibuprofen gebruik: (1 letter per
vakje).
Medicijn 1
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 2
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 3
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 5 (Pagina 1 van 3)
Patiëntcode./
medicatiecode
1. Wat is de datum vandaag? (dd-mm-jjjj)
-
-
2. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
1
geen pijn
2
3
milde pijn
matige pijn
4
5
veel pijn
extreme pijn
3. Hoe gevoelig voor aanraking zijn de delen van uw lichaam die door jicht zijn
aangedaan vandaag? (1 vakje volledig inkleuren)
1
2
3
4
5
niet
gevoelig
licht
gevoelig
redeijk
gevoelig
heel
gevoelig
extreem
gevoelig
4. Hoe gezwollen zijn de delen van uw lichaam die door jicht zijn aangedaan vandaag?
(1 vakje volledig inkleuren)
1
2
3
4
5
niet
gezwollen
enigszins
gezwollen
redelijk
gezwollen
heel
gezwollen
extreem
gezwollen
5. Wat vindt u van het beloop van uw klachten sinds het begin van deze jichtaanval? (1
vakje volledig inkleuren)
1
2
geheel
zeer veel
verdwenen verbeterd
3
4
veel
verbeterd
enigszins
verbeterd
5
6
7
8
9
niet
iets
veel
zeer veel
niet van
veranderd verslechterd verslechterd verslechterd toepassing
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 5 (Pagina 2 van 3)
6. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
Helemaal
geen pijn
0
1
2
3
4
5
6
7
8
9
10
Ondraaglijke
pijn
7. Als u denkt aan alle manieren waarop uw jicht u vandaag beïnvloedt, hoe gaat het
dan met u? (1 vakje volledig inkleuren)
Zeer slecht
Zeer goed
0
1
2
3
4
5
6
7
8
9
10
8. Heeft u last van bijwerkingen? Zo ja, noteer hieronder de bijwerkingen die u vandaag
ervaart: (1 letter per vakje)
9. Heeft u vandaag uw studiemedicatie ingenomen? (1 vakje volledig inkleuren)
Nee
Ja, alle medicijnen zoals voorgeschreven
Ja, maar gedeeltelijk/niet alles zoals voorgeschreven
10. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? Wilt u dit aangeven door een
verticaal streepje ( I ) te zetten op onderstaande lijn?
helemaal
geen pijn
ondraaglijke
pijn
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 5 (Pagina 3 van 3)
11. Heeft u de afgelopen 24 uur naast uw onderzoeksmedicatie, nog andere medicijnen
ingenomen om uw jichtaanval te bestrijden? Zo ja, noteer hieronder de medicatie die u
heeft ingenomen. Hieronder valt ook paracetamol en ibuprofen gebruik: (1 letter per
vakje).
Medicijn 1
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 2
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 3
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 6 (Pagina 1 van 3)
Patiëntcode./
medicatiecode
1. Wat is de datum vandaag? (dd-mm-jjjj)
-
-
2. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
1
2
3
4
5
geen pijn
milde pijn
matige pijn
veel pijn
extreme pijn
3. Hoe gevoelig voor aanraking zijn de delen van uw lichaam die door jicht zijn
aangedaan vandaag? (1 vakje volledig inkleuren)
1
2
3
4
5
niet
gevoelig
licht
gevoelig
redelijk
gevoelig
heel
gevoelig
extreem
gevoelig
4. Hoe gezwollen zijn de delen van uw lichaam die door jicht zijn aangedaan vandaag?
(1 vakje volledig inkleuren)
1
2
3
4
5
niet
gezwollen
enigszins
gezwollen
redelijk
gezwollen
heel
gezwollen
extreem
gezwollen
5. Wat vindt u van het beloop van uw klachten sinds het begin van deze jichtaanval? (1
vakje volledig inkleuren)
1
2
geheel
zeer veel
verdwenen verbeterd
3
4
veel
verbeterd
enigszins
verbeterd
5
6
7
8
9
niet
iets
veel
zeer veel
niet van
veranderd verslechterd verslechterd verslechterd toepassing
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 6 (Pagina 2 van 3)
6. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
Helemaal
geen pijn
0
1
2
3
4
5
6
7
8
9
10
Ondraaglijke
pijn
7. Als u denkt aan alle manieren waarop uw jicht u vandaag beïnvloedt, hoe gaat het
dan met u?
Zeer slecht
Zeer goed
0
1
2
3
4
5
6
7
8
9
10
8. Heeft u last van bijwerkingen? Zo ja, noteer hieronder de bijwerkingen die u vandaag
ervaart: (1 letter per vakje)
9. Heeft u vandaag uw studiemedicatie ingenomen? (1 vakje volledig inkleuren)
Nee
Ja, alle medicijnen zoals voorgeschreven
Ja, maar gedeeltelijk/niet alles zoals voorgeschreven
10. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? Wilt u dit aangeven door een
verticaal streepje ( I ) te zetten op onderstaande lijn?
helemaal
geen pijn
ondraaglijke
pijn
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 6 (Pagina 3 van 3)
11. Heeft u de afgelopen 24 uur naast uw onderzoeksmedicatie, nog andere medicijnen
ingenomen om uw jichtaanval te bestrijden? Zo ja, noteer hieronder de medicatie die u
heeft ingenomen. Hieronder valt ook paracetamol en ibuprofen gebruik: (1 letter per
vakje).
Medicijn 1
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 2
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 3
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 7 (Pagina 1 van 3)
Patiëntcode./
medicatiecode
1. Wat is de datum vandaag? (dd-mm-jjjj)
-
-
2. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
1
2
geen pijn
milde pijn
3
4
5
matige pijn
veel pijn
extreme pijn
3. Hoe gevoelig voor aanraking zijn de delen van uw lichaam die door jicht zijn
aangedaan vandaag? (1 vakje volledig inkleuren)
1
2
3
4
5
niet
gevoelig
licht
gevoelig
redelijk
gevoelig
heel
gevoelig
extreem
gevoelig
4. Hoe gezwollen zijn de delen van uw lichaam die door jicht zijn aangedaan vandaag?
(1 vakje volledig inkleuren)
1
2
3
4
5
niet
gezwollen
enigszins
gezwollen
redelijk
gezwollen
heel
gezwollen
extreem
gezwollen
5. Wat vindt u van het beloop van uw klachten sinds het begin van deze jichtaanval? (1
vakje volledig inkleuren)
1
2
geheel
zeer veel
verdwenen verbeterd
3
4
veel
verbeterd
enigszins
verbeterd
5
6
7
8
9
niet
iets
veel
zeer veel
niet van
veranderd verslechterd verslechterd verslechterd toepassing
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 7 (Pagina 2 van 3)
6. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? (1 vakje volledig inkleuren)
Helemaal
geen pijn
0
1
2
3
4
5
6
7
8
9
10
Ondraaglijke
pijn
7. Als u denkt aan alle manieren waarop uw jicht u vandaag beïnvloedt, hoe gaat het
dan met u? (1 vakje volledig inkleuren)
Zeer slecht
Zeer goed
0
1
2
3
4
5
6
7
8
9
10
8. Heeft u last van bijwerkingen? Zo ja, noteer hieronder de bijwerkingen die u vandaag
ervaart: (1 letter per vakje)
9. Heeft u vandaag uw studiemedicatie ingenomen? (1 vakje volledig inkleuren)
Nee
Ja, alle medicijnen zoals voorgeschreven
Ja, maar gedeeltelijk/niet alles zoals voorgeschreven
10. Hoeveel pijn heeft u vandaag als gevolg van uw jicht? Wilt u dit aangeven door een
verticaal streepje ( I ) te zetten op onderstaande lijn?
helemaal
geen pijn
ondraaglijke
pijn
52901
Versie 3 - 27/01/2016
ATTACG studie
JICHTAANVAL DAGBOEK - DAG 7 (Pagina 3 van 3)
11. Heeft u de afgelopen 24 uur naast uw onderzoeksmedicatie, nog andere medicijnen
ingenomen om uw jichtaanval te bestrijden? Zo ja, noteer hieronder de medicatie die u
heeft ingenomen. Hieronder valt ook paracetamol en ibuprofen gebruik: (1 letter per
vakje).
Medicijn 1
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 2
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
Medicijn 3
Naam medicijn volgens de verpakking
Hoeveel tabletten/injecties heeft u in de afgelopen 24 uur gebruikt van dit medicijn?
Dosering volgens de verpakking (kruis aan of de dosering in microgram of milligram is)
,
Microgram
Milligram
52901
Versie 3 - 27/01/2016
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - FYSIEK FUNCTIONEREN 1/2
De volgende vragen gaan over de invloed van uw ziekte op het functioneren in het dagelijks
leven. Kruis het antwoord aan dat het best beschrijft wat u meestal kon doen in de
AFGELOPEN WEEK.
zonder enige
moeite
met enige
moeite
met veel
moeite
onmogelijk
uit te voeren
AANKLEDING EN VERZORGING
-
Kunt u zichzelf aankleden, inclusief
veters strikken en knopen
dichtmaken?
-
Kunt u uw haren wassen?
OPSTAAN
-
Kunt u opstaan vanuit een rechte stoel?
-
Kunt u in en uit bed komen?
ETEN
-
Kunt u vlees snijden?
-
Kunt u een vol kopje of glas naar de
mond brengen?
-
Kunt u een nieuw pak melk openen?
LOPEN
-
Kunt u buitenshuis op een vlakke grond
wandelen?
-
Kunt u vijf traptreden oplopen?
Kruis aan welke HULPMIDDELEN u normaal gebruikt voor de bovenstaande activiteiten:
Wandelstok
Rollator / looprekje
Krukken
Rolstoel
Hulpmiddelen, gebruikt bij het aankleden (knoophaak,
ritssluiting-trekker, lange-steel schoenlepel, etc.)
Speciale of aangepaste hulpmiddelen bij eten of drinken
Speciale of aangepaste stoel
Overig, namelijk:
Kruis elke categorie aan waarvoor u normaal HULP VAN ANDEREN nodig heeft:
Aankleden / verzorging
Eten
Opstaan
Lopen
9373
Versie 3 - 27/01/2016
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - FYSIEK FUNCTIONEREN 2/2
Kruis het antwoord aan dat het best beschrijft wat u meestal kon doen IN DE AFGELOPEN
WEEK.
zonder enige
moeite
met enige
moeite
met veel
moeite
onmogelijk
uit te voeren
HYGIËNE
-
Kunt u zelf uw lichaam wassen en
afdrogen?
-
Kunt u in en uit bad komen?
- Kunt u op en van het toilet?
komen?
REIKEN
- Kunt u een 2,5 kg wegend voorwerp,
zoals een pak suiker, bereiken en
omlaaghalen van net boven uw hoofd?
-
Kunt u voorover buigen om kleren van de
vloer op te rapen?
GRIJPKRACHT
-
Kunt u auto-portieren openen?
-
Kunt u deksels van potten, die al eens
geopend zijn, losdraaien?
-
Kunt u een kraan open- en dichtdraaien?
ACTIVITEITEN
-
Kunt u boodschappen doen en winkelen?
-
Kunt u in en uit een auto komen?
-
Kunt u klusssen doen, zoals stofzuigen of
tuinieren?
Kruis aan welke HULPMIDDELEN u normaal gebruikt voor de bovenstaande activiteiten:
Verhoogd toilet
Lange-steel hulpmiddelen om iets te bereiken
Zitje in de badkuip
Lange-steel hulpmiddelen in de badkamer
Potdeksel-opener
Overig, namelijk:
Badkuip-muurstang
Kruis elke categorie aan waarvoor u normaal HULP VAN ANDEREN nodig heeft:
Wassen en toiletbezoek
Voorwerpen pakken en openen
Naar voorwerpen reiken
Boodschappen doen en klussen
9373
Versie 3 - 27/01/2016
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - GEZONDHEIDSSTATUS 1/4
Deze vragenlijst gaat over uw standpunten t.a.v. uw gezondheid. Wilt u elke vraag
beantwoorden door het juiste hokje aan te kruisen. Wanneer u twijfelt over het antwoord
op een vraag, probeer dan het antwoord te geven dat het meest van toepassing is.
1.
Hoe zou u over het algemeen uw gezondheid noemen?
uitstekend
zeer goed
goed
matig
slecht
2.
Hoe beoordeelt u nu uw gezondheid over het algemeen, vergeleken met een jaar geleden?
veel beter nu dan een jaar geleden
wat beter nu dan een jaar geleden
ongeveer hetzelfde nu als een jaar geleden
wat slechter nu dan een jaar geleden
veel slechter nu dan een jaar geleden
3.
De volgende vragen gaan over bezigheden die u misschien doet op een doorsnee dag. Wordt
u door uw gezondheid op dit moment beperkt bij deze bezigheden? Zo ja, in welke mate?
ja,
ernstig
beperkt
ja, een
beetje
beperkt
nee, helemaal niet
beperkt
a. Forse inspanning, zoals hardlopen, tillen
van zware voorwerpen, een veeleisende
sport beoefenen
b. Matige inspanning, zoals een tafel
verplaatsen, stofzuigen, zwemmen of fietsen
c. Boodschappen tillen of dragen
d. Een paar trappen oplopen
e. Eén trap oplopen
f. Bukken, knielen of hurken
g. Meer dan een kilometer lopen
h. Een paar honderd meter lopen
i. Ongeveer honderd meter lopen
j. Uzelf wassen of aankleden
9373
SF-36v2™ Health Survey 1992,2003 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated. All rights reserved.
SF-36® is a registered trademark of Medical Outcomes Trust.
(SF-36v2 Standard, Netherlands (Dutch))
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - GEZONDHEIDSSTATUS 2/4
4.
Hoe vaak heeft u in de afgelopen 4 weken, één van de volgende problemen bij uw werk of
andere dagelijkse bezigheden gehad, ten gevolge van uw lichamelijke gezondheid?
altijd
meestal
soms
zelden
nooit
a. U besteedde minder tijd aan werk
of andere bezigheden
b. U heeft minder bereikt dan u zou willen
c. U was beperkt in het soort werk of
andere bezigheden
d. U had moeite om uw werk of andere
bezigheden uit te voeren (het kostte
u bijvoorbeeld extra inspanning)
5.
Hoe vaak heeft u in de afgelopen 4 weken, één van de volgende problemen ondervonden bij
uw werk of andere dagelijkse bezigheden, ten gevolge van emotionele problemen (zoals
depressieve of angstige gevoelens)?
altijd
meestal
soms
zelden
nooit
a. U besteedde minder tijd aan werk
of andere bezigheden
b. U heeft minder bereikt dan u zou willen
c. U deed uw werk of andere bezigheden
niet zo zorgvuldig als gewoonlijk
6.
In hoeverre hebben uw lichamelijke gezondheid of emotionele problemen u gedurende de
afgelopen 4 weken gehinderd in uw normale omgang met familie, vrienden of buren, of bij
activiteiten in groepsverband?
helemaal niet
enigszins
nogal
veel
heel erg veel
9373
SF-36v2™ Health Survey 1992,2003 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated. All rights reserved.
SF-36® is a registered trademark of Medical Outcomes Trust.
(SF-36v2 Standard, Netherlands (Dutch))
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - GEZONDHEIDSSTATUS 3/4
7.
Hoeveel lichamelijke pijn heeft u de afgelopen 4 weken gehad?
geen
heel licht
licht
nogal
ernstig
heel ernstig
8.
In welke mate bent u de afgelopen 4 weken door pijn gehinderd in uw normale werk (zowel
werk buitenshuis als huishoudelijk werk)?
helemaal niet
enigszins
nogal
veel
heel erg veel
9.
Deze vragen gaan over hoe u zich voelt en hoe het met u ging in de afgelopen 4 weken. Wilt
u alstublieft bij elke vraag het antwoord geven dat het best benadert hoe u zich voelde?
Hoe vaak gedurende de afgelopen 4 weken...
altijd
meestal
soms
zelden
nooit
a. Voelde u zich levenslustig?
b. Was u erg zenuwachtig?
c. Zat u zo in de put dat niets u kon
opvrolijken?
d. Voelde u zich rustig en tevreden?
e. Had u veel energie?
f. Voelde u zich somber en neerslachtig?
g. Voelde u zich uitgeput?
h. Voelde u zich gelukkig?
i. Voelde u zich moe?
9373
SF-36v2™ Health Survey 1992,2003 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated. All rights reserved.
SF-36® is a registered trademark of Medical Outcomes Trust.
(SF-36v2 Standard, Netherlands (Dutch))
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - GEZONDHEIDSSTATUS 4/4
10. Hoe vaak hebben uw lichamelijke gezondheid of emotionele problemen u gedurende de
afgelopen 4 weken gehinderd bij uw sociale activiteiten (zoals vrienden of familie bezoeken,
etc.)?
altijd
meestal
soms
zelden
nooit
11. Hoe JUIST of ONJUIST is elk van de volgende uitspraken voor u?
volkomen
juist
grotendeels
juist
weet
ik niet
groten- volkomen
deels
onjuist
onjuist
a. Ik lijk wat gemakkelijker ziek te worden
dan andere mensen
b. Ik ben even gezond als andere mensen
die ik ken
c. Ik verwacht dat mijn gezondheid achteruit
zal gaan
d. Mijn gezondheid is uitstekend
9373
SF-36v2™ Health Survey 1992,2003 Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated. All rights reserved.
SF-36® is a registered trademark of Medical Outcomes Trust.
(SF-36v2 Standard, Netherlands (Dutch))
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - ZORGGEBRUIK (1/2)
1. Heeft u een bezoek gebracht aan een van onderstaande
gezondheidsmedewerkers SINDS UW VORIGE BEZOEK BIJ DE
REUMATOLOOG? Zo ja, geef aan hoe vaak u geweest bent.
Reumatoloog
Maagdarmlever arts
Psychiater
Verpleegkundig consulent /
onderzoeksverpleegkundige
Nefroloog
Fysiotherapeut
Physician assistant /
verpleegkundige specialist
Neuroloog
Ergotherapeut
Huisarts
Oncoloog
Oefentherapeut
Anestesioloog
Oogarts
Hydrotherapeut
Bedrijfsarts
Orthopeed
Podotherapeut
Cardioloog
Orthop. schoenmaker
Chirurg
Revalidatie arts
Dermatoloog
Kaakchirurg
Gynaecoloog
Uroloog
Hematoloog
Vaatchirurg
Internist
Maatschappelijk werker
Plastisch chirurg
Psycholoog
KNO arts
Psychotherapeut
Longarts
9373
Versie 2 - 30/06/2015
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - ZORGGEBRUIK (2/2)
2. Heeft u sinds uw vorige bezoek bij de
reumatoloog professionele hulp gekregen in verband
met persoonlijke verzorging of verpleging? Zo ja,
hoeveel uur gemiddeld per week?
3. Heeft u sinds uw vorige bezoek bij de
reumatoloog gebruik gemaakt van betaalde
huishoudelijke hulp, bijvoorbeeld alfa hulp? Zo ja
hoeveel uur gemiddeld per week?
4. Heeft u sinds uw vorige bezoek bij de
reumatoloog hulp gekregen van uw partner, familie of
vrienden in verband met persoonlijke verzorging of het
huishouden als gevolg van jicht? Zo ja hoeveel uur
gemiddeld per week?
5. Wat is uw arbeidssituatie (meerdere antwoorden mogelijk)
Betaald werk
VUT/pensioen
WAO/WIA
Vrijwilligerswerk
Geen van bovenstaande
6. Heeft u een van onderstaande behandelingen ondergaan
sinds uw vorige bezoek bij de reumatoloog? Zo ja, geef
het aantal aan
Maken van een röntgen foto
Het maken van een MRI
Maken van een echo
Het maken van een CT-scan
7. Bent u sinds uw vorige bezoek bij de reumatoloog in
een van onderstaande zorginstellingen opgenomen geweest?
Zo ja, geef de duur van de opname dan in dagen. Het is niet
nodig om dagopnames voor de toediening van medicatie te
noteren
Academisch ziekenhuis
Dagen
Intensive care academisch ziekenhuis
Dagen
Algemeen ziekenhuis
Dagen
Intensive care algemeen ziekenhuis
Dagen
Revalidatiecentrum
Dagen
Verpleeghuis
Dagen
9373
Versie 2 - 30/06/2015
ATTACG studie
VRAGENLIJST VOOR PATIËNTEN - WERK PRODUCTIVITEIT (1/1)
1. Hebt u op dit moment een baan (werkt u tegen betaling)? Indien
nee, kies nee en ga verder naar vraag 6
Ja
Nee
2. Hoeveel uur was u tijdens de afgelopen zeven dagen afwezig van
uw werk in verband met uw jicht? Reken hierbij de uren die u gemist
hebt op dagen waarop u ziek was, later op het werk kwam, vroeger
wegging enz. Reken hier de tijd die u gemist hebt omdat u aan
deze studie meedoet niet bij
uur
3. Hoeveel uur bent u tijdens de afgelopen 7 dagen afwezig
geweest van uw werk vanwege een andere reden, zoals vakantie,
feestdagen, tijd die u vrij hebt genomen om aan deze studie deel te
nemen?
uur
4. Hoeveel uur hebt u in de afgelopen 7 dagen daadwerkelijk
gewerkt? (indien 0, ga door naar vraag 6)
uur
5. Hoezeer heeft uw jicht in de afgelopen 7 dagen uw productiviteit
beïnvloed TERWIJL U AAN HET WERK WAS? (denk aan de dagen
waarop u beperkt werd in de hoeveelheid of het soort werk dat u kon
doen, minder bereikte dan u gewild had of niet zo zorgvuldig kon
werken als gewoonlijk.)
Jicht had geen
invloed op
mijn werk
0
1
2
3
4
5
6
7
8
9
Jicht heeft
mij volledig
belet mijn
werk te doen
10
6. Hoezeer heeft uw jicht tijdens de afgelopen 7 dagen uw
vermogen beïnvloed uw normale dagelijkse activiteiten, buiten uw
baan, uit te voeren? Met normale bezigheden bedoelen we
activiteiten die u gewoonlijk uitvoert zoals werk in en rondom het
huis, winkelen, voor de kinderen zorgen, lichaamsbeweging,
studeren, enz. Denk aan de momenten waarop u beperkt werd in
de hoeveelheid of soort activiteiten die u kon doen of minder
bereikte dan u gewild had.
Jicht had geen
invloed op
mijn
activiteiten
0
1
2
3
4
5
6
7
8
9
10
Jicht heeft
mij volledig
belet mijn
activiteiten
te doen
9373
Versie 2 - 30/06/2015
DSMB Charter
“ATTACG: Anakinra versus treatment as usual in the treatment of acute gout”
Dossier: NL52526.044.15 / EudraCT number: 2015-000696-27
Introduction
This charter is for the Data Safety Monitoring Board (DSMB) which will act in advisory capacity to
prof. dr. M.A.F.J. van de Laar, Medisch Spectrum Twente, Ariënsplein 1 7511 JX, Enschede,
conducting the ATTACG study funded by ZonMw. The purpose of this document is to describe the
roles and responsibilities of the DSMB, describe board processes and describe the method of
reporting.
DSMB Roles and Responsibilities
The DSMB roles and responsibilities are:
-
To perform ongoing safety surveillance of the study participants
To advise prof. dr. M.A.F.J. van de Laar on if breaking the randomization (treatment) code is
needed if cases of SAE or SUSARs arise during the trial
To report to prof. dr. M.A.F.J. van de Laar on the safety of anakinra during the trial
To decide to prematurely stop the study if felt the safety of the patients is being jeopardized
The DSMB will discharge itself from its duties when the last participant completes the study.
Membership
The DSMB will consist of 3 advisory members:
1. Prof. dr. Rene Westhovens, rheumatologist, Universiteit Ziekenhuis Leuven, Belgium.
2. Dr. Mark Reinders, hospital pharmacist, Atrium Medisch Centrum, Heerlen, the Netherlands.
3. Prof. dr. Thomas Bardin, rheumatologist, Hôpital Lariboisière, Paris, France / professor of
rheumatology, Université Paris VII.
There are no financial, scientific, or other conflict of interest with the study.
Before the trial
The DSMB will be informed about its duties and the study before the start of the trial by means of
this DSMB charter and the final study protocol. If needed, the principal investigator (tel. 053-487
2450 / email: m.vandelaar@mst.nl) or coordinating investigator (tel. 06-2855-4650 email:
c.a.janssen@utwente.nl) may be contacted if any aspects of the study and duties of the DSMB are
not clear.
During the trial
The DSMB will review safety data when 50 patients allocated to the anakinra treatment study group
have been included in the study. At this point in time the committee will review the safety data on
the documented and frequency of side effects and/or AE/SAE among patients using anakinra. The
coordinating investigator will provide the necessary data to the DSMB. A recommendation regarding
the outcome of this evaluation will be made available to the principal investigator.
At any point in time an emergency evaluation of the safety data may be called upon (by DSMB
chairman or principal investigator) should safety issues or other unanticipated problems arise. In
cases of SAE or SUSARs and the sponsor feels breaking the randomization (treatment) code may
need to be broken in order to treat the patient, the sponsor may decide to contact the DSMB for
advice regarding this matter.
A recommendation to terminate the study may be made by the DSMB at any time. The DSMB should
communicate such a recommendation to the principal investigator immediately by telephone and
confirmed by email (tel. 053 – 487 2450 / email: m.vandelaar@mst.nl).
Reporting
A formal report, including an advice and/or recommendation for continuation or modification of the
study will be prepared by the DSMB and when finalized be submitted to the principal investigator.
The principal investigator is responsible for distributing the DSMB recommendations to all other
study investigators. A copy of all the DSMB recommendations will be sent to the authorizing METC.
When the principal investigator decides not to implement the recommendations, besides the copy, a
clear and convincing reasoning for why the advice has not been followed should be included and sent
to the authorizing METC as well.
Confidentiality
All materials, discussions and proceedings of the DSMB are completely confidential. Members and
other participants in the DSMB meetings are expected to maintain confidentiality.